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ABSTRACT
Influenza virus is a contagious respiratory virus responsible for seasonal epidemics
and several catastrophic pandemics in the last century. Its genome is comprised of
negative sense, single-stranded RNA and, after entering the cell, it is capable of
hijacking the host cellular machinery for reproducing its own genetic material. The
activation of cellular defenses against influenza viral infection are triggered upon viral
entry and help regulate the course of viral infection. This study focused on the interplay
between the influenza A virus and the cellular SUMOylation system during viral
infection. The first part of this dissertation deals with the relevance of NS1 SUMOylation
during viral infection. We demonstrate that in studies performed in an animal model,
infection with viruses containing a non-SUMOylatable NS1 resulted in increased clinical
symptoms, morbidity, and mortality. Furthermore, the inhibition of NS1 SUMOylation
enabled viral replication in a broad range of organs and increased pathology of
influenza viral infection. Together, these results suggest that NS1 SUMOylation may be
a factor contributing to the regulation of viral pathogenicity. The second part of this
dissertation deals with NS1‘s role in triggering an increase in cellular SUMOylation. We
show that the ability of NS1 to be SUMOylated directly correlates to its ability to trigger a
global increase in cellular SUMOylation. Furthermore, we show that infection with
vaccinia virus and lymphocyctic choriomeningitis virus are also able to trigger a less
dramatic, but still detectable, increase in global cellular SUMOylation. Together, these
results suggest that increases in cellular SUMOylation are frequently triggered by viral
infection and may be a component of the cellular protective responses against viral
infection. The last part of this dissertation deals with the evaluation of a novel fusion
vii

protein capable of specifically increasing the SUMOylation of NS1 (known as NS1(1-87)Ubc9) as a potential therapeutic agent against influenza viral infection. Our results
indicate that the two methods used to deliver the NS1(1-87)-Ubc9 artificial SUMO ligase
are effective. Overall, our results suggest that the global increase in cellular
SUMOylation, which is associated with NS1 SUMOylation, may constitute a defense
mechanism mounted by the host to inhibit the progression of influenza viral infection.

viii

TABLE OF CONTENTS
ACKNOWLEDGEMENTS.................................................................................................v
ABSTRACT......................................................................................................................vii
TABLE OF CONTENTS...................................................................................................ix
LIST OF TABLES............................................................................................................xii
LIST OF FIGURES.........................................................................................................xiii
CHAPTER 1: INTRODUCTION........................................................................................1
1.1 Influenza and its impact on human health.......................................................1
1.2 General properties of influenza virus...............................................................4
1.3 Composition of the viral particle.......................................................................5
1.4 Influenza viral life cycle....................................................................................8
1.5 Immune response to influenza viral infection.................................................11
1.6 Role of NS1 in influenza viral infection..........................................................16
1.7 Limitations of anti-influenza measures...........................................................21
1.8 SUMO: the Small Ubiquitin-like MOdifier.......................................................23
1.9 Protein modification by SUMOylation............................................................25
1.10 The cellular SUMOylation system and disease............................................29
1.11 The cellular SUMOylation system and bacterial pathogens.........................30
1.12 The cellular SUMOylation system and viral pathogens................................31
1.13 The cellular SUMOylation system and RNA viruses....................................35
1.14 The cellular SUMOylation system and influenza virus.................................37
1.15 Significance and Aims..................................................................................38

ix

CHAPTER 2: MUTATIONS AFFECTING NS1 SUMOYLATION DURING INFLUENZA
VIRAL INFECTION ALTER VIRAL FITNESS AND PATHOGENICITY............................41
2.1 Introduction....................................................................................................41
2.2 Materials and Methods...................................................................................48
2.3 Results...........................................................................................................57
2.4 Discussion......................................................................................................71
2.5 Acknowledgements........................................................................................74
CHAPTER 3: SUMOYLATION OF VIRAL PROTEINS RESULTS IN AN INCREASE IN
CELLULAR SUMOYLATION OF INFECTED CELLS.....................................................75
3.1 Introduction....................................................................................................75
3.2 Materials and Methods...................................................................................80
3.3 Results...........................................................................................................87
3.4 Discussion....................................................................................................105
3.5 Acknowledgements......................................................................................108
CHAPTER 4: THE ARTIFICIAL SUMO LIGASE IS EFFECTIVELY EXPRESSED IN
CELLS AND COULD ACT AS A POTENTIAL THERAPEUTIC AGAINST INFLUENZA A
VIRAL INFECTION.......................................................................................................109
4.1 Introduction..................................................................................................109
4.2 Materials and Methods.................................................................................112
4.3 Results.........................................................................................................118
4.4 Discussion....................................................................................................129
4.5 Acknowledgements......................................................................................132
CHAPTER 5: FINAL CONCLUSIONS AND FUTURE DIRECTIONS...........................133
x

5.1 Overview and Final Conclusions..................................................................133
5.2 Future Directions..........................................................................................136
REFERENCES.............................................................................................................139
APPENDIX A................................................................................................................163
List of Abbreviations...........................................................................................163
List of Developed Constructs.............................................................................169
Formula for Reed-Muench Method....................................................................170
CURRICULUM VITA.....................................................................................................171

xi

LIST OF TABLES

Table 1.1 Proteins encoded by viral RNA segments........................................................7
Table 2.1 Properties of the recombinant viruses developed and their modifications.....46
Table 2.2 Pathology report from influenza infected lungs..............................................70
Table 3.1 Influenza A viral strains used in studies..........................................................92
Table 5.1 Properties of plasmids developed and their modifications...........................138

xii

LIST OF FIGURES

Figure 1.1 Diagram of influenza viral replication............................................................10
Figure 1.2 The SUMOylation pathway...........................................................................28
Figure 2.1 Diagram of the 12-plasmid based reverse genetics system.........................45
Figure 2.2. Generation of the shifted NS constructs......................................................47
Figure 2.3 SUMOylation of NS1 affects viral fitness......................................................63
Figure 2.4 Overall experimental approach.....................................................................64
Figure 2.5 Impairment of NS1 SUMOylation does not affect survival but caused
increased weight loss during viral infection in vivo.........................................................65
Figure 2.6 Impairment of NS1 SUMOylation results in replication in a broader range of
organs............................................................................................................................66
Figure 2.7 Viral replication in in vivo results in a mixed population of viruses...............67
Figure 2.8 Viruses containing a non-SUMOylatable NS1 significantly enhance changes
in gross pathology and histopathology in lungs from infected mice (4 days postinfection).........................................................................................................................68
Figure 2.9 Viruses containing a non-SUMOylatable NS1 significantly enhance changes
in gross pathology and histopathology in lungs from infected mice (6 days postinfection).........................................................................................................................69
Figure 3.1 NS1 proteins from different influenza A viruses exhibit varying levels of
SUMOylation...................................................................................................................93
Figure 3.2 Quantification of SUMOylation of NS1 proteins from different influenza
strains.............................................................................................................................94
xiii

Figure 3.3 SUMOylated NS1 proteins are able to trigger an increase in cellular
SUMOylation...................................................................................................................95
Figure 3.4 Influenza infections ex vivo and in vivo exhibit a global increase in cellular
SUMOylation...................................................................................................................96
Figure 3.5 Animals infected with WSN/T7T7[NS1~NS2] virus exhibit increases in
cellular SUMOylation......................................................................................................97
Figure 3.6 Animals infected with WSN/T7T7[NS1K70AK219A~NS2] virus do not exhibit
increases in cellular SUMOylation..................................................................................98
Figure 3.7 Overall experimental approach.....................................................................99
Figure 3.8 Animals infected with different influenza A viruses exhibit increases in
cellular SUMOylation....................................................................................................100
Figure 3.9 Increases in cellular SUMOylation during LCMV infection.........................101
Figure 3.10 Infection with LCMV results in an increase in cellular SUMOylation within in
125 to 150 kD molecular weight range.........................................................................102
Figure 3.11 Increases in cellular SUMOylation during LCMV infection are not due to
changes in the level of SUMO conjugating enzyme Ubc9............................................103
Figure 3.12 Infection with Vaccinia virus and LCMV results in the appearance of two
new SUMOylated bands...............................................................................................104
Figure 4.1 Transfection of the purified protein form of the artificial SUMO ligase can be
achieved in multiple cell lines.......................................................................................122
Figure 4.2 The purified protein form of the artificial SUMO ligase is located in the
cytoplasm of transfected cells.......................................................................................123

xiv

Figure 4.3 Transfection with purified GST or GST-ASL results in decreased viral
replication.....................................................................................................................124
Figure 4.4 The artificial SUMO ligase is expressed at low levels in transduced
cells...............................................................................................................................125
Figure 4.5 The artificial SUMO ligase is expressed within the cytoplasm of transfected
cells...............................................................................................................................126
Figure 4.6 Plasmid transfection with HA-Ubc9 or artificial SUMO ligase (NS1(1-87)-Ubc9)
results in decreased viral infection................................................................................127
Figure 4.7 Expression of the artificial SUMO ligase increases upon viral infection and
results in higher viral titers............................................................................................128

xv

CHAPTER 1: INTRODUCTION

1.1 Influenza and its impact on human health
Influenza infections affect 5 to 20% of the population and causes an average of
52,000 deaths and 1.68 million hospitalizations each year in the United States alone
with almost half of those cases being reported in children under the age of four and
adults over the age of sixty-five (Lowen, Mubareka et al. 2007, Meunier and von
Messling 2011, Pillet, Kobasa et al. 2011, Fauci and Collins 2012, Ortigoza, Dibben et
al. 2012). Globally, there are an estimated 250,000 to 500,000 deaths due to influenza
infection every year, with an increased number in pandemic years (Pillet, Kobasa et al.
2011, Fauci and Collins 2012, Maines, Belser et al. 2012).
In the last century, four pandemics have caused widespread morbidity and
mortality, occurring in 1918, 1957, 1968, and the most recent, in 2009 (Maines, Belser
et al. 2012). Emergence of influenza strains to which the human population has little or
no pre-existing immunity can be associated with widespread and potentially severe
disease pandemics (Kuchipudi, Dunham et al. 2011), as demonstrated by both the 1918
“Spanish Flu” and the H1N1 influenza pandemic of 2009. The 1918 “Spanish Flu” killed
between 50 and 100 million people worldwide (Fauci and Collins 2012). The 2009 H1N1
influenza pandemic resulted in approximately 414,000 confirmed cases and 5,000
deaths worldwide (Kobinger, Meunier et al. 2010). It is likely that the actual numbers are
substantially higher due to recent changes requiring that severe cases be confirmed by
laboratory diagnosis (Kobinger, Meunier et al. 2010).
1

It has been shown that reassortment between the pandemic swine-origin strain of
H1N1 influenza virus and the highly pathogenic avian-origin strain of H5N1 influenza
virus could lead to the creation of highly pathogenic viruses capable of spreading
efficiently among humans with deadly and pandemic potential (Neumann, Noda et al.
2009, Octaviani, Ozawa et al. 2010). The recent emergence of a novel influenza virus
(subtype H7N9) in provinces of China is the product of a novel reassortment with clear
pandemic potential (Guan, Farooqui et al. 2013, Kageyama, Fujisaki et al. 2013, Nicoll
and Danielsson 2013).
The H7N9 subtype has shown increased transmission between poultry and
humans and contains genetic markers that have been associated with improved
replication in mammals resulting in severe respiratory illness and, in some cases, death
(Guan, Farooqui et al. 2013, Kageyama, Fujisaki et al. 2013, Nicoll and Danielsson
2013). The H7N9 subtype influenza viruses contained mutations within one of the
surface proteins and the ion channel that rendered current anti-viral treatments
ineffective (Kageyama, Fujisaki et al. 2013). In addition, the surface proteins of the
H7N9 subtype were found to contain several mutations within the receptor-binding site
of the surface proteins that enabled systemic viral spread (Guan, Farooqui et al. 2013,
Kageyama, Fujisaki et al. 2013). An additional mutation within one of the surface
proteins of the H7N9 subtype contributed to increased binding to human-type receptors,
while a specific lysine residue within one of the polymerase subunits was required for
efficient viral replication (Kageyama, Fujisaki et al. 2013).
Furthermore, other factors, in addition to those identified in the H7N9 subtype,
have been found to contribute to the pathogenicity of influenza viruses. Highly
2

pathogenic strains of influenza virus contain a consecutive group of basic amino acids
in the cleavage site in one of the surface proteins and have been shown to play a role in
viral spread (Bosch, Orlich et al. 1979, Bosch, Garten et al. 1981, Garten, Bosch et al.
1981). Similarly, the four C-terminal residues of the non-structural protein have been
shown to contribute virulence and pathogenesis of avian influenza strains (Jackson,
Hossain et al. 2008).
The genetic markers identified in influenza viruses play a significant role in
determining the pattern of disease in the respiratory tract and the host range of
influenza viral infection (Kuiken, van den Brand et al. 2010). For example, human
influenza viruses infect the ciliated epithelial cells in the trachea and bronchi often
resulting in mild inflammation of the upper respiratory tract (Ibricevic, Pekosz et al.
2006, Kuiken, van den Brand et al. 2010). In contrast, mouse adapted strains of
influenza viruses infect the ciliated bronchiolar epithelial cells and alveoli of the lower
respiratory tract resulting in virus-induced pneumonia (Ibricevic, Pekosz et al. 2006,
Kuiken, van den Brand et al. 2010). The differences in human and mouse tropism of
influenza infection are determined by the genetic markers encoded in viral proteins and
their influence on host receptors (Ibricevic, Pekosz et al. 2006). Thus, understanding the
interaction between host cellular factors and influenza viral proteins, and their relevance
during infection, would allow for the development of novel, effective therapeutic
interventions targeted against seasonal and pandemic strains of influenza.
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1.2 General properties of influenza virus
Influenza belongs to the family Orthomyxoviridae and can be categorized into
three groups: A, B, and C. Influenza C viruses cause mild respiratory illnesses and are
not responsible for causing epidemics (Prevention 2012). Influenza A and B viruses are
responsible for seasonal epidemics and pandemics, however, only influenza A can be
further classified by antigenic variation based on the hemagglutinin (HA) and
neuraminidase (NA) proteins, shortened to H and N respectively, when indicating the
subtype of the virus (Steinhauer 2002, Herfst, Schrauwen et al. 2012, Prevention 2012,
Angel, Kimble et al. 2013). Currently, there are 17 H variants and 10 N variants which
can give rise to hundreds of combinations of virus subtypes, (Herfst, Schrauwen et al.
2012, Rahim, Selman et al. 2013). Virus subtypes H1 to H4, H6, and H8 to H17 are
associated with low pathogenic influenza viruses (Herfst, Schrauwen et al. 2012). Most
viruses comprised of subtypes H5 and H7 are considered low pathogenic influenza
viruses in poultry, however some of these subtypes can be high pathogenic viruses
once domestic birds are infected and undergo reassortment with other influenza strains
(Herfst, Schrauwen et al. 2012, Prevention 2013).
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1.3 Composition of the viral particle
The influenza A genome is comprised of eight segments of single-stranded,
negative-sense RNA that encode at least 11 viral proteins, including two non-structural
proteins, NS1 and NEP (also known as NS2), and nine structural proteins, as listed in
Table 1 (Steinhauer 2002, Chan, Lin et al. 2006, Lowen, Mubareka et al. 2007, Hale,
Randall et al. 2008, Ozawa and Kawaoka 2011, Arranz, Coloma et al. 2012, Backstrom
Winquist, Abdurahman et al. 2012, Herfst, Schrauwen et al. 2012, Ortigoza, Dibben et
al. 2012, Rahim, Selman et al. 2013, Santos, Pal et al. 2013). Most of the RNA
segments encode a single protein, with the exception of segments 7 and 8, and in some
viral strains, segment 2, which encode two proteins (Hale, Randall et al. 2008,
Backstrom Winquist, Abdurahman et al. 2012, Herfst, Schrauwen et al. 2012, Chua,
Schmid et al. 2013). Nine influenza viral proteins have been identified to make up the
influenza virion (Shaw, Stone et al. 2008). The viral particle is surrounded by a lipid
membrane acquired from the host and that is heavily populated with the viral proteins
HA and NA. The ion channel protein, M2, is also embedded within the membrane, but at
much lower levels as compared to HA and NA (Shaw, Stone et al. 2008). The most
abundant viral protein in the virion is M1 which forms a brick-like membrane matrix that
lies just below the membrane and is responsible for supporting and connecting the
internal viral ribonucleoprotein (vRNP) core and external membrane proteins (Shaw,
Stone et al. 2008, Ran, Chen et al. 2013). The vRNPs are comprised of viral RNA
coated by the viral nucleoprotein, NP, and bound in a closed conformation in which each
end of the viral RNA interacts with a single copy of the trimeric polymerase complex
(PB2, PB1, PA) similar to a hairpin structure (Shaw, Stone et al. 2008, Arranz, Coloma
5

et al. 2012). The final viral protein found within the virion is the nuclear export protein,
NEP, which is responsible for the nuclear export of vRNPs through its association with
M1 and critical to the virus life cycle (Chua, Schmid et al. 2013).
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Table 1.1 Proteins encoded by viral RNA segments
RNA
Viral
Segment Protein
1

Function

Gene Size
(bp)

PB2

Basic polymerase 2; polymerase component; host cap binding

2341

PB1

Basic polymerase 1; polymerase component; catalytic subunit

PB1-F2

Apoptosis induction; interferon antagonist; modulate polymerase
activity
Acidic polymerase; cap snatching endonuclease; replication of viral
genome

2

2341

3

PA

4

HA

Hemagglutinin; antigenic determinant; surface glycoprotein; binds host
receptors on cell membrane; fusion with endosomal membrane

1778

5

NP

Nucleoprotein; viral ribonucleoprotein (vRNP) complex component; viral
assembly; RNA synthesis

1565

6

NA

Neuraminidase; antigenic determinant; surface glycoprotein; release of
new viral particles by cleaving sialic acids

1413

M1

Matrix protein; viral assembly

M2

Transmembrane ion-channel; viral disassembly upon infection

NS1

Non-structural protein; interferon antagonist; suppresses host gene
expression; modulates mRNA splicing and translation

7

2233

1027

8
NEP

Nuclear export protein; trafficking of vRNPs for viral assembly

7

890

1.4 Influenza viral life cycle
Viral infection occurs when viral particles bind to sialic acid receptors on the host
cell via receptor binding sites in an uncleaved form of hemagglutinin (HA), HA0 (Skehel
and Wiley 2000). Upon binding, receptor-mediated endocytosis is activated allowing the
virus to enter the cell in an endocytic vesicle (Skehel and Wiley 2000, Samji 2009, Das,
Aramini et al. 2010). The low pH of the endosome causes a conformational change and
cleavage event of HA0 resulting in the exposure of its two subunits, HA1 and HA2,
which contain the receptor binding domain and the fusion peptide, respectively. The
HA2 fusion peptides bring the viral and endosomal membranes into close proximity
resulting in the fusion of the two membranes (Samji 2009, Das, Aramini et al. 2010).
The low pH also causes an influx of protons to enter the viral particle through the M2 ion
channel thus causing the vRNPs to dissociate from the M1 matrix (Samji 2009, Das,
Aramini et al. 2010).
Influenza is distinct from other RNA viruses in that it is able to replicate and
transcribe its vRNAs in the nucleus (Ozawa and Kawaoka 2011). Once the vRNPs
dissociate from M1, the vRNPs are released into the cytoplasm and transported into the
nucleus (Das, Aramini et al. 2010). The viral RNA (vRNA) segments contain a region of
approximately 12 to 13 terminal nucleotides at the 3’ and 5’ ends that are highly
conserved among each of the eight RNA segments which may serve as key elements in
transcription and replication events (Ozawa and Kawaoka 2011). Once inside the
nucleus, the viral polymerase activates transcription by a 5’-“cap snatching” mechanism
from nascent mRNA strands (Dias, Bouvier et al. 2009). This occurs when the PB2
subunit binds the mRNA strand at the 5’ cap and PA cleaves 10-15 nucleotides
8

downstream from the cap (Das, Aramini et al. 2010). The cap structure is then used to
prime viral mRNA transcripts, thus initiating transcription of the viral mRNAs by PB1 and
replication of full-length cRNAs (Samji 2009, Das, Aramini et al. 2010, Scull and Rice
2010). The cRNAs will serve as the template for progeny vRNAs (Scull and Rice 2010).
Following transcription of the viral mRNAs, they are shuttled out of the nucleus into the
cytoplasm for translation. Transcription of the viral genome is separated into two
phases, early, in which viral proteins necessary for replication are synthesized, and late,
in which all other viral proteins needed for viral assembly are synthesized. After
translation, the early viral proteins, PB2/PB1/PA (RdRp), NP, NS1, and NEP, are
shuttled back to the nucleus to facilitate the transcription of late viral genes, mainly the
ones coding for the surface proteins, HA, NA, M1, and M2, and replication of the cRNA
into progeny vRNA. In addition, translation of the surface membrane proteins, HA, NA,
and M2, occurs at the rough Endoplasmic Reticulum (rER) thus allowing them to enter
the secretory pathway where they undergo extensive processing (Ran, Chen et al.
2013). In the rER, the surface proteins are glycosylated, transported to the Golgi, and
targeted to the apical domain of the cell membrane (Das, Aramini et al. 2010). The
newly synthesized progeny vRNAs, are transported out of the nucleus to the cell
membrane, mediated by the M1-NS2 complex, where they are incorporated into new
viral particles (Ran, Chen et al. 2013). Once at the plasma membrane, vRNPs are
incorporated into new viral particles (Ran, Chen et al. 2013) that bud out and are
released when sialic acid residues are cleaved by NA (Das, Aramini et al. 2010). Figure
1.1 illustrates the life cycle of influenza virus.

9

Figure 1.1 Diagram of influenza viral replication. The virus binds to sialic acid
residues on the host cell membrane and enters the cell via endocytosis. Fusion of the
viral membrane with the endosome membrane causes the release of the viral RNPs
into the cytoplasm for export into the nucleus. Viral proteins are produced. New vRNAs
are synthesized and shuttled to the membrane for budding. Viral particles are released
from the infected cells.
Image from P Palese, ML Shaw, "Orthomyxoviridae: The Viruses and Their Replication", Fields Virology,
5th edition D.M. Knipe and P.M. Howley, Editors. 2006, Lippencott Williams and Wilkins: Philadelphia
ISBN-10: 0-7817-6060-7, 2001, 1647-1689.
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1.5 Immune response to influenza infection
The first line of defense for a host against viral infection is the recognition of
various pathogen-associated molecular patterns (PAMPs) that lead to the activation of
cellular innate immune responses, including the interferon (IFN)-response (Ehrhardt and
Ludwig 2009, McKinstry, Strutt et al. 2011). PAMPs are short sequences within
pathogens and are recognized by pathogen recognition receptors (PRRs) (Kumar,
Kawai et al. 2011). There are several families of PRRs including toll-like receptors
(TLRs), which are considered to be the primary sensors of pathogens, and RIG-I-like
receptors (RLRs) such as RIG-I, MDA5, and LGP2 (Kumar, Kawai et al. 2011). The
recognition of PAMPs by TLRs and RLRs leads to the activation of signaling pathways
of the innate immune response (Akira and Hemmi 2003). Several factors contribute to
the immune response to viral infection including the nature of the pathogen itself, the
route of infection, whether it is a chronic persisting or acute infection, and how the virus
is presented to specific T cells for the adaptive response (Brown, Roman et al. 2004).
Moderate increases of immune activation in virus-infected individuals may favor viral
clearance; however a hyper-activated immune response may lead to detrimental effects
for the host (Jiang, Zhang et al. 2010). The balance between the key players during
immune activation ultimately determines the extent and progression of infection
(Gannage and Munz 2009, Rossman and Lamb 2009).
CD4 T cells have been shown to act as helper cells to regulate innate immunity
and as direct effectors of cell-mediated protection (McKinstry, Strutt et al. 2011). CD4 T
cells regulate innate immunity early after influenza infection, which has been shown to
decrease viral titers (Brown, Dilzer et al. 2006, McKinstry, Strutt et al. 2011). The
11

secretion of antiviral cytokines and cell-mediated cytotoxic activity by CD4 T cells has
also been shown to control viral titers (Brown, Dilzer et al. 2006, Brown 2010, Nayak,
Richards et al. 2010) while orchestrating the host immune response (Jiang, Zhang et al.
2010). The main family of cytokine mediators responsible for initiating a cellular immune
response to viral infection are IFNs (Le Page, Genin et al. 2000). IFNs are crucial for
controlling viral replication and limiting the spread of the virus (Meunier and von
Messling 2011). Upon viral infection, viral PAMPs are recognized by the TLRs or RLRs
stimulating the production of IFNs, via activation of interferon regulatory transcription
factors, IRF3 and IRF7 (Kumar, Kawai et al. 2011). IFN production results in the
upregulation of several hundred genes that produce an antiviral state (Randall and
Goodbourn 2008). Some of the upregulated genes encode enzymes endowed with
antiviral activity, as exemplified by protein kinase R (PKR) and 2’, 5‘-oligoadenylate
synthetase (OAS), two key factors activated upon IFN stimulation. PKR is responsible
for phosphorylating the alpha subunit of the eukaryotic translational initiation factor 2
(eIF2 alpha), which inhibits translation and activates autophagy, resulting in degradation
of the cell (Randall and Goodbourn 2008). Additionally, OAS binds and activates RNase
L leading to the degradation of cellular and viral RNAs (Randall and Goodbourn 2008).
Distinct cytokine secretion patterns are used to separate CD4 T cells into subsets,
which provide insights on their functional diversity and their contribution to an immune
response (Strutt, McKinstry et al. 2009). The development of each subset is controlled
by a unique transcription factor and once the developmental program is established, the
genes that promote the other subsets are silenced (Brown 2010). For example, the
secretion of the primary cytokine IFN-gamma upon viral infection leads to the
12

differentiation of CD4 T cells into T helper 1 cells while suppressing T helper 2 cell
differentiation (Schoenborn and Wilson 2007).
It has been shown that CD4 T cell responses are not determined, to a significant
extent, by the localization of the viral proteins within the infected cell, but by the strength
of the immunodominant epitopes that are presented by these viral proteins (Nayak,
Richards et al. 2010). Earlier studies had identified T cell epitopes to influenza in which
HA was the major antigen for CD4 T cells (Lamb and Green 1983). However, recently it
has been shown that M1 and PB1 are the major antigens for CD4 T cells (Ge, Tan et al.
2010). Although the other viral proteins elicit an immune response, it is significantly
lower than the response elicited by M1 and PB1 (Ge, Tan et al. 2010).
The HA envelope protein plays a major role in viral entry into the cells, thus
playing a critical role in virulence (Surls, Nazarov-Stoica et al. 2010); however, both
capsid proteins, HA and NA, are highly variable (McKinstry, Strutt et al. 2011). It has
been suggested that the ability of viral proteins HA and NA to induce cytotoxic activity
has been severely underestimated (Rahim, Selman et al. 2013). In a study by
Subbramanian et al. (Subbramanian, Basha et al. 2010), the variable and conserved
regions of HA were investigated in order to determine their contribution to the CD4 T cell
response from the pandemic 2009 H1N1 and seasonal H1N1 influenza viruses. It was
found that the variable regions of the 2009 pandemic virus induced a highly diverse HAspecific T cell response with a significant subset of individuals that demonstrated higher
levels of several proinflammatory cytokines and chemokines compared to the
responses induced by the seasonal influenza virus (Hale, Steel et al. 2010,
Subbramanian, Basha et al. 2010). It was also found that the conserved regions of both
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the pandemic 2009 H1N1 virus and seasonal H1N1 influenza virus induced comparable
levels of HA-specific T cell responses, suggesting that CD4 T cells preferentially
respond to variable regions of HA viral proteins, more than conserved regions
(Subbramanian, Basha et al. 2010). In addition, the 2009 H1N1 pandemic virus was
also able to replicate more efficiently thus causing increased levels of morbidity and
mortality as compared to the seasonal influenza virus (Hale, Steel et al. 2010).
CD4 T cells have been shown to act as helpers by driving optimal CD8 T cell
responses (McKinstry, Strutt et al. 2011). Earlier studies also identified T cell epitopes to
influenza in which NP and M1 were the major antigens for CD8 T cells (Lamb and
Green 1983, Yewdell, Bennink et al. 1985, Gotch, Rothbard et al. 1987). It is important
to note that it is not surprising that M1 is a major antigen for both CD4 and CD8 T cells.
M1 is the most highly conserved viral protein across many strains of influenza. Other
influenza viral proteins, including PB1, PB2, PA, and NP, have also been shown to be
highly conserved across many strains of influenza, most likely due to their highly
regulated functional constraints and different selection pressures, supporting that
virulence is a polygenic trait (Hale, Steel et al. 2010, McKinstry, Strutt et al. 2011). It has
been shown that immune cytotoxic CD8 T cells are directed predominantly against the
internal viral proteins, which are commonly shared and highly conserved among many
strains of influenza virus (Furuya, Chan et al. 2010).
Influenza-specific CD8 T cells proliferate and promote the elimination of the virus
and host recovery via the production of pro-inflammatory cytokines, which are elicited
by highly activated dendritic cells, which are essential for an efficient immune response
(McKinstry, Strutt et al. 2011, Meunier and von Messling 2011). Viral infection causes an
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robust upregulation of IFN-stimulated genes related to antigen presentation leading to
the stimulation of dendritic cells (Tisoncik, Billharz et al. 2011). This stimulation causes a
release of proinflammatory cytokines and chemokines that migrate to lymph nodes
where they present pathogen-specific antigens to T helper and cytotoxic cells, thus
accelerating T-cell responses and initiating the destruction of virus infected cells through
cytotoxic mechanisms (Hale, Randall et al. 2008, Hatta, Hershberger et al. 2010,
Tisoncik, Billharz et al. 2011, Valkenburg, Rutigliano et al. 2011). Cell-mediated cytotoxic
activity occurs via two major mechanisms including cell surface receptor binding of Fas
with Fas ligand, and granule exocytosis, in which T cells secrete perforin and granzyme
B after recognition of an antigen. Both of these mechanisms result in the activation of
caspases, which in turn, induce apoptosis in target cells (Brown, Dilzer et al. 2006).
Highly pathogenic influenza virus triggers CD8 T cells to induce the production of
proinflammatory cytokines interleukin (IL)-6 and tumor necrosis factor (TNF)-alpha thus
inducing cellular apoptosis through the TNF-related apoptosis-inducing ligand (TRAIL)/
TRAIL receptor-dependent mechanism (Brincks, Kucaba et al. 2008, Hatta,
Hershberger et al. 2010, Meunier, Embury-Hyatt et al. 2012). It has been shown that the
lack of CD8 T cells leads to increased viral replication and eventual morbidity, which
suggests that CD8 T cells are required for viral clearance (Brown, Roman et al. 2004).
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1.6 Role of NS1 in influenza viral infection
Viruses have evolved numerous strategies in order to evade the host defense
responses mounted upon viral infection. For influenza virus, the non-structural 1 (NS1)
protein is the virally encoded antagonist responsible for neutralizing cellular innate
immune responses (Garcia-Sastre, Egorov et al. 1998, Meunier and von Messling 2011,
Backstrom Winquist, Abdurahman et al. 2012, Ortigoza, Dibben et al. 2012). The NS
gene segment is the smallest gene segment of the influenza genome and encodes at
least two viral proteins, an unspliced product, NS1, and a spliced product, nuclear
export protein, NEP (Hale, Randall et al. 2008, Backstrom Winquist, Abdurahman et al.
2012, Chua, Schmid et al. 2013). NS1 is a 26 kDa protein that ranges in length from
219 to 237 amino acids (Rahim, Selman et al. 2013) and is expressed early during viral
infection (Thomas, Kranjec et al. 2011). Viruses lacking NS1 are able to efficiently
replicate in interferon-deficient cell lines, however, are attenuated and do not cause
disease, implicating NS1 as a factor responsible for pathogenicity (Meunier and von
Messling 2011, Backstrom Winquist, Abdurahman et al. 2012, Ortigoza, Dibben et al.
2012). NS1 is predominantly localized in the nucleus which allows for exerting its
multiple functions associated to regulating viral infection and circumventing host
immune defenses (Li, Yamakita et al. 1998).
NS1 exhibits two distinct globular domains linked by a flexible, unstructured linker
sequence. Each globular domain acts as a functional domain with the N-terminal (amino
acids 1-73) acting as an RNA binding domain (RBD) and the C-terminal (amino acids
74-230) acting as an effector domain (ED), mediating the interactions with host-cellular
proteins and stabilizing the RNA binding domain (Wang and Krug 1996, Hale, Randall et
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al. 2008). The RNA-binding domain is required for counteracting the IFN response
(Dundon and Capua 2009). This domain functions by sequestering double stranded
RNA (dsRNA) preventing the activity of the OAS and PKR, two key regulators of the
antiviral response (Talon, Horvath et al. 2000, Salvatore, Basler et al. 2002, Kochs,
Garcia-Sastre et al. 2007, de Vries, Haasnoot et al. 2009). The RBD of NS1 is
responsible for out-competing with OAS for dsRNA preventing the activation of the
RNase L pathway contributing to the suppression of IFN-beta synthesis (Hale, Randall
et al. 2008). NS1 blocks the activation of PKR by preventing a conformational change
that is normally required for the activation of transcription factors, such as eIF2-alpha,
and, ultimately, the inhibition of protein synthesis (Wang and Krug 1996, Talon, Horvath
et al. 2000, Salvatore, Basler et al. 2002, Kochs, Garcia-Sastre et al. 2007, Jackson,
Hossain et al. 2008). NS1 has been shown co-precipitate with the retinoic acid-inducible
gene product I, RIG-I, suggesting a potential protein-protein interaction which is
stabilized by the presence of 5’-triphosphorylated single stranded RNA (ssRNA) (Hale,
Randall et al. 2008, Jackson, Hossain et al. 2008, Meunier and von Messling 2011).
Furthermore, the interaction between NS1 and RIG-I inhibits activation of transcription
factors IRF3, IRF7, NF-κB and c-Jun/ATF, which are critical for the expression of IFNbeta and an effective immune response (Kochs, Garcia-Sastre et al. 2007, Hale,
Randall et al. 2008, Jackson, Hossain et al. 2008, de Vries, Haasnoot et al. 2009,
Tisoncik, Billharz et al. 2011). Additionally, NS1 has been implicated in G0/G1 cell cycle
arrest in an IFN-dependent manner (Jiang, Wang et al. 2013). This is achieved either by
directly binding the Ras homolog gene family member A (RhoA), a small GTPase that
controls many cell cellular functions, or by downregulating the transcription factor NF-κB
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(Jiang, Wang et al. 2013). Additionally, NS1‘s ability to bind dsRNA has been shown to
interfere with the RNA-silencing antiviral response (RSAR) in an NS1-ED dependent
manner as another measure to counteract host antiviral mechanisms (Li, Li et al. 2004).
This demonstrates that the ED is responsible for enhancing the antagonistic properties
of NS1 by stabilizing its dimeric structure, which is required for RNA binding (Dundon
and Capua 2009).
The ED of NS1 is also responsible for mediating interactions with a number of
host cellular proteins and contains the nuclear export and import sequences as well as
a nucleolar localization signal (Dundon and Capua 2009). The ED of NS1 has been
shown to play a role in disrupting the activation of RIG-I by targeting TRIM25, a RING
E3 ubiquitin ligase and antiviral molecule critical for RIG-I mediated induction of the
type-1 IFN response and activation of dendritic cells (Jackson, Hossain et al. 2008,
Hale, Steel et al. 2010, Tisoncik, Billharz et al. 2011, Di Pietro, Kajaste-Rudnitski et al.
2013). NS1 binds TRIM25 via its ED preventing the formation of protein complexes and
multimerization (Di Pietro, Kajaste-Rudnitski et al. 2013). The C-terminal four residues
of NS1 encode a potential PDZ-binding motif involved in protein-protein interactions that
can modulate a range of cell-signaling pathways, including transport, localization,
complex formation, and cell polarity organization among others (Hale, Randall et al.
2008, Jackson, Hossain et al. 2008, Dundon and Capua 2009). The EPEV and ESEV
C-terminal residues have been shown to play a role in binding PDZ-domain containing
proteins interfering with cell-signaling (Krug 2006, Jackson, Hossain et al. 2008,
Thomas, Kranjec et al. 2011) and disrupting cellular tight junctions through binding of
Scribble and DlgI, factors involved in the induction of apoptosis, thus leading to an
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overall increase in lung pathology (Thomas, Kranjec et al. 2011, Soubies, Hoffmann et
al. 2013). NS1 proteins containing C-terminus extensions that alter the PDZ-binding
motif have been associated with attenuated virulence implicating the C-terminus of NS1
as an indicator of pathogenicity (Thomas, Kranjec et al. 2011, Meunier, Embury-Hyatt et
al. 2012, Soubies, Hoffmann et al. 2013).
NS1 contains several other protein interaction sites including SH2 and SH3
domains, as well as recognition sites for the kinases CK2 and MAPK (Dundon and
Capua 2009, Thomas, Kranjec et al. 2011). SH3 domains are responsible for mediating
protein-protein interactions and are commonly found in proteins involved in the
regulation of cell signaling pathways, cytoskeletal organization, and membrane
trafficking (Dundon and Capua 2009). One of the cell signaling components targeted by
NS1 is phosphatidylinositol-3-kinase (PI3K) (Kochs, Garcia-Sastre et al. 2007, Li,
Anderson et al. 2008, Ehrhardt and Ludwig 2009, Thomas, Kranjec et al. 2011). The
activation of PI3K supports viral replication in two phases: 1) early phase, regulating
viral attachment or uptake, and 2) intermediate phase, following expression of NS1
(Ehrhardt and Ludwig 2009). The SH3 domain of NS1 binds the inter-SH2 domain of the
p85-beta subunit of PI3K, thus leading to its activation and regulation of kinase
phosphorylation events, including the phosphorylation of the serine/threonine kinase,
Akt (Hale, Randall et al. 2008, Li, Anderson et al. 2008, Ehrhardt and Ludwig 2009,
Thomas, Kranjec et al. 2011). These phosphorylation events lead to the induction of
downstream signaling pathways responsible for cell proliferation, migration,
differentiation, and the suppression of cellular apoptosis (Li, Anderson et al. 2008).
Furthermore, the ability of NS1 to bind adapter proteins Crk and CrkL has been
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associated with enhanced PI3K signaling supporting the role of PI3K/Akt signaling in the
regulation of viral infection (Li, Anderson et al. 2008).
Another function associated to the ED of NS1 is the ability to regulate viral and
cellular processing of mRNAs (Backstrom Winquist, Abdurahman et al. 2012). Many
NS1 proteins are able to inhibit mRNA splicing and nuclear export of host-cellular
proteins by preventing polyadenylation of mRNAs and through binding of the zinc-finger
regions in the 30 kDa subunit of the cleavage and polyadenylation specificity factor
(CPSF30) and the poly-A binding protein II (PABPII) (Kochs, Garcia-Sastre et al. 2007,
Dundon and Capua 2009, Hale, Steel et al. 2010, Meunier and von Messling 2011,
Tisoncik, Billharz et al. 2011, Backstrom Winquist, Abdurahman et al. 2012, Selman
2012). These interactions prevent the splicing, polyadenylation, and transport of the
cellular mRNAs into the cytoplasm, thus inhibiting translation, and have been suggested
to be the major reason for the shutoff of host cellular protein synthesis observed during
influenza infections (Salvatore, Basler et al. 2002, Hale, Randall et al. 2008, Dundon
and Capua 2009, Backstrom Winquist, Abdurahman et al. 2012). Furthermore, the
ability of NS1 to form inhibitory complexes with other components of the nuclear export
machinery, including NXF2, p15, Rael, E1B-AP5, and Nup98, support NS1’s role in
regulating the export of cellular mRNAs (Hale, Randall et al. 2008). NS1 also has the
ability to modulate expression levels of proteins via its ability to act as a general
translational enhancer (Salvatore, Basler et al. 2002). NS1 is able to recruit translation
factors, such as eIF4G1, eIF4F, hStaufen, and PABPI, to the 5’-untranslated region
(UTR) of viral mRNAs in order to form multi-protein translation complexes to
preferentially increase viral translation (Hale, Randall et al. 2008, Pal 2010).
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1.7 Limitations of anti-influenza measures
There are two current measures against the influenza virus: 1) vaccines and 2)
antiviral drugs. Vaccines are a widely accepted weapon against viral infection due to
their ability to elicit a strong immune response to circulating strains of the virus. Each
year the vaccine has to be modified so that it will protect against influenza viruses that
research indicates will be most prevalent during the upcoming season. However,
vaccines are limited in their ability to protect against new strains that are generated
through antigenic drift or antigenic shift. Viruses can undergo antigenic drift in which
small changes are accumulated over time, thus producing viruses that may be
unrecognizable to the body’s immune system (Prevention 2012). Antigenic shift is a
sudden, major change in the virus composition resulting in a virus that most people
have little or no immune response against

(Brooke, Ince et al. 2013). In 1957, two

strains of influenza, an avian H2N2 and a circulating H1N1, exchanged gene segments
thus generating an H2N2 viral strain that triggered an H2N2 pandemic (Masurel 1969).
Subsequently, in 1968, the H2N2 pandemic strain combined with an avian H3 strain to
produce the H3N2 pandemic (Scholtissek, Rohde et al. 1978, Kawaoka, Krauss et al.
1989). Thus, due to the continually changing genetic composition of the virus, caused
by both, genetic drift and genetic shift, vaccines lose effectiveness approximately after
every influenza season and are likely to not be readily available in the event of new
pandemics (Angel, Kimble et al. 2013).
Current FDA-approved anti-viral drugs belong to three main groups: 1)
neuraminidase inhibitors, 2) M2 ion-channel inhibitors, and, 3) the most recent, a viral
RNA synthesis inhibitor (Ortigoza, Dibben et al. 2012). The neuraminidase inhibitors,
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Oseltamivir and Zanamivir, act by binding neuraminidase proteins thus blocking its
enzymatic activity and preventing the release of newly formed viral particles. The M2
ion-channel inhibitors, Amantidine and Rimantidine, act by blocking the activity of the
M2 ion-channel, thus preventing the release of vRNPs into the cytoplasm (Krug and
Aramini 2009). The viral RNA synthesis inhibitor, Favipiravir (T-705), acts as a purine
analogue thus inhibiting the synthesis of viral RNA (Ortigoza, Dibben et al. 2012). The
available anti-viral drugs function by inhibiting structural components of the virus which
are subject to mutations introduced by the error-prone viral RdRp. In a study by
Moscona (Moscona 2009), a single mutation, H274Y, in the NA viral protein target,
rendered the anti-viral drug Oseltamivir fully ineffective against influenza viral infection.
Currently, 98.6% and 100% of circulating 2009 H1N1 and H3N2 strains of influenza
virus are susceptible to the neuraminidase inhibitors, Oseltamivir and Zanamivir,
respectively, while all of the 2009 H1N1 and H3N2 strains of influenza are resistant to
the M2 ion-channel inhibitors, Amantidine and Rimantidine (Moscona 2009, Prevention
2012).
Despite current influenza treatments, it is critical to develop novel treatments that
are effective against influenza virus independent of the subtype, strain, or antigenic
properties. One alternative is the development of therapies targeting cellular
mechanisms utilized for viral propagation, which will be less likely to be affected by
genomic mutations or reassortment. One such cellular mechanism is the cellular
SUMOylation system, in which the Small Ubiquitin-like MOdifier (SUMO) protein is
conjugated to target proteins, a modification that has been reported to modulate protein
function (Pal, Santos et al. 2011).
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1.8 SUMO: the Small Ubiquitin-like MOdifier
SUMOylation is a reversible, post-translational modification in which a SUMO
protein is covalently attached to a lysine residue within the target protein. SUMO was
discovered by numerous investigators independently of one another; thus, it was initially
known under several different names including PIC1 (Boddy, Howe et al. 1996), UBL1
(Shen, Pardington-Purtymun et al. 1996), Sentrin (Gong, Kamitani et al. 1997), and
hSMT3C (Lapenta, Chiurazzi et al. 1997, Wilson and Rangasamy 2001). Matunis et al.
(Matunis, Coutavas et al. 1996) reported the first protein target of SUMO (then referred
to as GMP1), a nuclear transport component, RanGAP1. In humans, SUMO, an 11 kDa
protein, has four distinct homologs: SUMO 1 through 4. SUMO homologs 1 through 3
are ubiquitously expressed, while the SUMO 4 is mainly expressed in the kidneys,
lymph nodes, and spleen. SUMO 2 and 3 are 97% identical and are commonly referred
to as SUMO2/3, while SUMO 1 only shares 50% identity with SUMO 2/3 (GeissFriedlander and Melchior 2007). SUMO 2 and 3 are able to form poly-SUMO chains, an
ability conferred by their extended N-terminal tail (Song, Durrin et al. 2004). In contrast,
SUMO 1 is not able to form poly-SUMO chains; however, it is able to serve as a polySUMO chain terminator (Hannoun, Greenhough et al. 2010). Recent studies have
proposed a potential mechanism that explains why some proteins are preferentially
modified by SUMO 2/3 over SUMO1 (Meulmeester, Kunze et al. 2008, Sarge and ParkSarge 2009). This mechanism involves an interaction between SUMO and SUMOinteraction motifs (SIMs), in an manner analogous to the mechanism in which ubiquitin
is able to interact with ubiquitin-interaction motifs (UIMs) (Meulmeester, Kunze et al.
2008, Sarge and Park-Sarge 2009). SUMO interacting motifs are generally short
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sequences of hydrophobic residues that are surrounded by acidic ones and contribute
to the SUMOylation of a protein thanks to their ability to bring into close-proximity Ubc9associated SUMO molecules hence leading to an enhanced SUMOylation (Song, Durrin
et al. 2004, Hecker, Rabiller et al. 2006, Song, Bhattacharya et al. 2006, GeissFriedlander and Melchior 2007, Merrill, Melhuish et al. 2010). Similar to the ubiquitininteraction motif, defined as L-A-L-A-L, SUMO-interacting motifs are defined as V/I/L-XV/I-V/I or the inversion (Swanson, Kang et al. 2003, Song, Durrin et al. 2004, Hecker,
Rabiller et al. 2006, Song, Bhattacharya et al. 2006, Geiss-Friedlander and Melchior
2007, Merrill, Melhuish et al. 2010).
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1.9 Protein modification by SUMOylation
As illustrated in Figure 2, SUMO proteins are expressed as immature precursor
proteins. In order for SUMO proteins to be conjugated to target proteins, a stretch of
amino acids on the C-terminus must be cleaved by a SUMO-specific protease, SENP, to
reveal a di-glycine motif that indicates the C-terminus of the mature protein (Wilson and
Rangasamy 2001, Geiss-Friedlander and Melchior 2007, Drag and Salvesen 2008,
Bekes and Drag 2012). Once SUMO has been cleaved into its mature form, the E1
activating enzyme, SAE1/2, activates SUMO in an ATP-dependent manner in which a
thioester bond is formed between the C-terminal carboxy group of SUMO and the
catalytic cysteine residue of SAE2 (Geiss-Friedlander and Melchior 2007, Hannoun,
Greenhough et al. 2010).
SUMO is then transferred from SAE2 to the E2 conjugating enzyme, Ubc9, an 18
kDa monomeric enzyme that is specific for SUMO conjugation (Wilson and Rangasamy
2001, Geiss-Friedlander and Melchior 2007, Hannoun, Greenhough et al. 2010). A
thioester bond is then formed between the C-terminal carboxy group of SUMO and the
catalytic cysteine residue, C93, of Ubc9 (Wilson and Rangasamy 2001, GeissFriedlander and Melchior 2007, Hannoun, Greenhough et al. 2010). SUMO is then
transferred from Ubc9 to the target protein, in which an isopeptide bond is formed
between the carboxy group of SUMO and the ε-amino group on a lysine residue in the
target protein. The target lysine residues are usually located with in a consensus
sequence, Ψ-K-X-E, in which the Ψ represents a large hydrophobic amino acid,
followed by a lysine residue (K), any amino acid (X) and a glutamic acid (E) residue.
Numerous SUMO target proteins contain only one target lysine residue, however, a few,
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such as the cytomegalovirus (CMV) IE2 protein, contain multiple target residues (Wilson
and Rangasamy 2001). Approximately 40% of known SUMOylated proteins are
SUMOylated at lysine residues that are not located within a SUMO consensus
sequence (Hannoun, Greenhough et al. 2010). This process may occur with or without
the participation of a SUMO E3 ligase, which are enzymes that catalyze the transfer of
SUMO from Ubc9 to the target protein either by activation of Ubc9 or by bringing Ubc9
and the target protein into close proximity with each other (Rosas-Acosta, Langereis et
al. 2005, Geiss-Friedlander and Melchior 2007, Sarge and Park-Sarge 2009, Hannoun,
Greenhough et al. 2010).
SUMO can be removed from the target protein by proteolytic cleavage, thus
making SUMOylation a reversible modification. The SUMO released upon cleavage can
be used for conjugation with another target protein (Geiss-Friedlander and Melchior
2007, Drag and Salvesen 2008, Bekes and Drag 2012). The main family of SUMO
proteases is the sentrin-specific proteases (SENPs) (Drag and Salvesen 2008). There
are seven different isoforms of SENP, including SENPs 1-3, SENP6 and SENP7. Each
of the SENP isoforms contain a Ulp domain at the C-terminus, which is responsible for
cleaving the isopeptide bond between SUMO and the target protein (Hannoun,
Greenhough et al. 2010). The hydrolase activity at the C-terminus of each of the SENPs
varies, suggesting that each SENP may differentially regulate the maturation and
activity of the different SUMO homologs (Wilson and Rangasamy 2001, Hannoun,
Greenhough et al. 2010). SENPs tightly regulate the levels of SUMOylation of target
proteins and are thought to regulate the levels of free SUMO in the cell (Hannoun,
Greenhough et al. 2010, Ribet and Cossart 2010).
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Post-translational modifications, such as glycosylation, phosphorylation,
methylation, acetylation, and SUMOylation, are highly conserved processes that have
been shown to affect protein activity, cellular localization, homeostasis maintenance,
signal transduction, and protein-protein interactions, either by creating or masking
existing binding sites (Geiss-Friedlander and Melchior 2007, Bekes and Drag 2012).
Most of the targets for SUMOylation are nuclear proteins with critical roles in biological
processes and SUMOylation has been associated with regulating functions such as
transcription, ribosome biogenesis, receptor function, cell cycle control, and DNA repair
(Rosas-Acosta, Langereis et al. 2005, Drag and Salvesen 2008, Bekes and Drag 2012).
Previous studies have shown that various diseases and pathogens are using these
post-translational mechanisms to their advantage, suggesting a potential role that may
be relevant for influenza viral infection (Ehrhardt and Ludwig 2009, Bekes and Drag
2012).
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Figure 1.2. The SUMOylation pathway. 1) SUMO is generated as an immature
precursor protein requiring cleavage by a SUMO protease. 2) In an ATP dependent
manner, SUMO is activated by the heterodimeric E1 protein. 3) SUMO is then
transferred to the E2 conjugating enzyme, Ubc9. SUMO is conjugated to its target
protein at a lysine residue. This reaction may be facilitated by an E3 ligase, but ligases
are not required. 4) SUMO can then be cleaved from the target protein and re-enter the
pathway.
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1.10 The cellular SUMOylation system and disease
The discovery that a pathogen could modulate the post-translational modification
machinery occurred almost 50 years ago when the diphtheria toxin from
Corynebacterium diphtheriae was discovered to be able to ribosylate ADP leading to the
inhibition of the host elongation factor 2 (EF-2) (Ribet and Cossart 2010). Since then,
other post-translational modifications have been reported to be modulated, induced, or
counteracted by pathogen-associated virulence factors (Ribet and Cossart 2010).
Besides its role in mediating critical processes within the cell, recent studies have
implicated the SUMOylation system as a target for pathogen-associated virulence
factors (Sarge and Park-Sarge 2009, Ribet and Cossart 2010). Proteins involved in
human diseases, such as huntingtin (Huntington’s disease), ataxin-1 (Spinocerebellar
ataxia type 1), tau, α-synuclein, DJ-1 (Alzheimer’s and Parkinson’s disease), and
superoxide dismutase 1 (Amyotrophic lateral sclerosis), have all been identified as
protein targets of the cellular SUMOylation system (Sarge and Park-Sarge 2009). Other
proteins, including amyloid precursor protein (Alzheimer’s) and lamin A (HutchisonGilford Progeria Syndrome, among others), have also been identified as SUMO targets,
and the loss of SUMO modification of these proteins have been associated with
elevated amyloid-β levels and cardiomyophathies, respectively (Sarge and Park-Sarge
2009). Increased levels of the E2 conjugating enzyme, Ubc9, and the deconjugating
enzyme, SENP, have also been linked to several human cancers, including prostate and
thyroid cancer, and can lead to increased cancer growth (Sarge and Park-Sarge 2009).
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1.11 The cellular SUMOylation system and bacterial pathogens
Bacterial pathogens have been known to interfere with may different posttranslational modifications in order to promote their own survival (Ribet and Cossart
2010). For example, the protein YopJ/P from the Yersenia species and the XopD and
AvrXv4 proteins from Xanthomonas campestris have been shown to enhance SUMO
deconjugation from host proteins (Ribet and Cossart 2010, Ribet and Cossart 2010,
Wimmer, Schreiner et al. 2012). Similarly, listeriolysin O (LLO) from Listeria
monocytogenes, in addition to perfringolysin (PFO) from Clostridium perfringens and
pneumolysin (PLO) from Streptococcus pneumoniae, directly impair the SUMOylation
pathway by enhancing the degradation of Ubc9, which results in increased infection
(Citro and Chiocca 2010, Ribet and Cossart 2010, Wimmer, Schreiner et al. 2012).
However, when SUMO was overexpressed within the cell, there was a decrease in
Listeria infection, suggesting an important role for the regulation of the cellular
SUMOylation system during bacterial infection (Ribet and Cossart 2010). The
SUMOylation pathway has also been suggested in modifying rhoptry proteins in
Toxoplasma gondii, which may play a role in host cell invasion, cyst development and
maintenance, and pathogenesis (Braun, Cannella et al. 2009).
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1.12 The cellular SUMOylation system and viral pathogens
In addition to bacterial pathogens, viruses are also able to interfere with the host
SUMOylation system through either inhibiting de novo SUMOylation or enhancing
deconjugation of SUMO from target proteins (Boggio and Chiocca 2006). Viruses may
also extort the host SUMOylation system in order to create an environment that is
favorable for viral replication, which may require SUMO modification for transcriptional
regulation or the nuclear localization of proteins (Boggio and Chiocca 2006). Most
SUMOylated viral proteins are either intermediate-early or early nuclear proteins and
are preferentially modified by SUMO1 (Rosas-Acosta, Langereis et al. 2005, Boggio
and Chiocca 2006). The viral immediate-early proteins that have been shown to be
SUMOylated include IE1 and IE2 from human cytomegalovirus (HCMV); Zta, Rta, and
BZLF1 from Epstein-Barr virus (EBV); and IE1 from human herpes virus 6 (HHV6)
(Wilson and Rangasamy 2001, Boggio and Chiocca 2006). The first viral proteins
observed to interact with the cellular SUMOylation system were the herpes simplex
virus (HSV) immediate-early protein ICP0 (infected cell protein 0) and the HCMVimmediate early 1 protein (IE1), the first viral protein found to be SUMOylated (Wilson
and Rangasamy 2001, Boggio and Chiocca 2006, Wimmer, Schreiner et al. 2012). Both
the ICP0 protein from HSV and the IE1 protein from HCMV are responsible for
regulating early events during the lytic cycle and induce dispersion of promyleocytic
leukemia nuclear bodies (PML NBs), sub-nuclear structures associated with
transcriptionally active regions (Boggio and Chiocca 2006, Wimmer, Schreiner et al.
2012). Though both ICP0 and IE1 have the ability to interact with PMLs and to
deSUMOylate them, the mechanism in which this is executed is unique to each protein
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(Boggio and Chiocca 2006, Wimmer, Schreiner et al. 2012). An orthologue of ICP0,
ORF61, from varicella-zoster virus (VSV) contains SUMO interacting motifs which may
facilitate the reduction of PML NBs (Wimmer, Schreiner et al. 2012). The function of IE1
is not dependent upon being SUMOylated, but this modification does contribute to its
full activity and overall viral replication by promoting the expression of IE2, the
transcriptional activator of the HCMV lytic cycle (Boggio and Chiocca 2006). In addition,
the IE2 protein contains a SUMO interacting motif that necessary for its modification by
SUMO (Wimmer, Schreiner et al. 2012). Another protein from HCMV, pp71, induces the
SUMOylation of a cellular transcription co-repressor, Daxx (Hwang and Kalejta 2011).
This SUMOylation event is required for the interaction between pp71 and Daxx (Hwang
and Kalejta 2011). The Zta (BZLF1) and Rta viral proteins from EBV are early proteins
that are responsible for activating early genes allowing the virus to enter the lytic cycle
(Wilson and Rangasamy 2001, Boggio and Chiocca 2006, Hagemeier, Dickerson et al.
2010, Wimmer, Schreiner et al. 2012). When SUMOylated, Zta and Rta have been
shown to induce the dispersion of PML NBs by out-competing PMLs for free SUMO and
by increasing its trans-activation activity, respectively (Boggio and Chiocca 2006,
Hagemeier, Dickerson et al. 2010, Wimmer, Schreiner et al. 2012). The K-bZIP (KSHVbasic leucine zipper) viral protein of Kaposi’s sarcoma associated herpesvirus (KSHV)
also has the ability to be SUMOylated thus allowing for exertion of its transcriptional
repression activity by recruiting Ubc9 to specific viral target promoters in an E3 ligaselike manner (Boggio and Chiocca 2006, Ribet and Cossart 2010, Wimmer, Schreiner et
al. 2012). The avian adenoviral protein, Gam1, inhibits the SUMOylation pathway by
binding to the E1 heterodimer preventing its function (Boggio and Chiocca 2006, Citro
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and Chiocca 2010, Ribet and Cossart 2010, Ribet and Cossart 2010, Wimmer,
Schreiner et al. 2012).
Other viral proteins that are SUMOylated during infection are the papillomavirus
(PV) E1 and E2 proteins, in which SUMOylation plays a role in the nuclear localization
of these proteins (Wilson and Rangasamy 2001, Rosas-Acosta, Langereis et al. 2005,
Boggio and Chiocca 2006, Wu, Roark et al. 2008, Wu, Bian et al. 2009, Wimmer,
Schreiner et al. 2012). The SUMOylation of PV-E1 is enhanced by the protein inhibitor
of activated STAT (signal transducer and activator of transcription) (PIAS) family of E3
ligases, in particular, Miz1 (PIASχβ) (Rosas-Acosta, Langereis et al. 2005). Two
retroviruses, Moloney murine leukemia virus (MuLV) and human immunodeficiency virus
type 1 (HIV-1) contain viral proteins that have been shown to be targets of the cellular
SUMOylation system (Boggio and Chiocca 2006). The viral Gag genes in both viruses,
which encode the Gag capsid proteins responsible for the formation of the nuclear viral
DNA forms and viral propagation, have been shown to be modified by SUMO (Boggio
and Chiocca 2006). Although SUMOylation is not required for the functionality of these
proteins, the overexpression of SUMO within the cell caused a decrease in infectivity,
suggesting that SUMOylation plays an important regulatory role during infection (Boggio
and Chiocca 2006). Other regulatory proteins expressed by HIV-1, Tat and Rev, have
also been associated with the cellular SUMOylation system. The SUMO modification of
Tat is required for stabilization, allowing for the penetration of lymphocytes, while SUMO
modification of Rev exhibits inhibition of function (Boggio and Chiocca 2006). Other viral
regulatory proteins that are known to be SUMOylated include the E3L and A40R
proteins from poxvirus vaccinia virus (VV) and the Tax protein from human T-cell
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leukemia virus type 1 (HTLV-1) (Boggio and Chiocca 2006, Wimmer, Schreiner et al.
2012).

34

1.13 The cellular SUMOylation system and RNA viruses
In terms of RNA viruses, our knowledge of the mechanistic role of the
SUMOylation pathway during viral infection is very limited (Wimmer, Schreiner et al.
2012). In the family Bunyaviridae, several different species of the genus Hantavirus,
including Hantaan virus (HTNV), Tula virus (TULV) and Seoul virus (SEOV), were
investigated for potential targets of SUMOylation. Studies of these different species
identified the nucleocapsid protein (NP) as a target for the SUMOylation pathway.
Although there is no evidence that this protein is SUMOylated during viral infection, it is
able to directly interact with the SUMO pathway components, SUMO 1, Ubc9 and
certain E3 ligases (Wimmer, Schreiner et al. 2012). The nucleocapsid (N) protein from
the Coronaviridae family, SARS (severe acute respiratory syndrome) coronavirus
(SARS-CoV), has been identified as a SUMO modified protein target (Wimmer,
Schreiner et al. 2012). The N protein is able to directly bind Ubc9, and may regulate its
E2 conjugating activity. Data suggests that SUMOylation of the N protein plays a role in
the induction of viral ribonucleoprotein complex formation and nucleocapsid assembly
(Wimmer, Schreiner et al. 2012). Two other viral proteins, the VP35 from Ebola Zaire
virus (Filviridae family) and the envelope protein (env) from Dengue virus (Flaviviridae
family), have been shown to directly interact with members of the SUMOylation pathway
(Wimmer, Schreiner et al. 2012). The VP35 protein is able to directly bind PIAS1
inducing the SUMOylation of IFN-regulatory factor 7 (IFN7) thus decreasing its
transcription activating function upon the promoter (Wimmer, Schreiner et al. 2012). The
Dengue env protein is able to directly interact with Ubc9 in a SUMOylation independent
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manner, however the functional relevance for this interaction has yet to be elucidated
(Wimmer, Schreiner et al. 2012).
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1.14 The cellular SUMOylation system and influenza virus
Influenza virus is one of the few RNA viruses that are able to replicate within the
nucleus of host cells making it a potential target for the host cellular SUMOylation
system. The viral protein, NS1, has been shown to be modified by ISGylation, a
member of ubiquitin-like modifier family, in which its major downstream effectors are
members of the host antiviral response (Tang, Zhong et al. 2010, Pal, Santos et al.
2011). In a study by Wu et al. (Wu, Jeng et al. 2011), M1 was found to be SUMOylated
at residue 242. In addition, SUMOylation of M1 was shown to be relevant for viral
replication and for the formation of the M1/NEP-vRNP complex, which is required for the
nuclear export of vRNPs (Wu, Jeng et al. 2011). Recent studies have also demonstrated
that NS1 is an authentic SUMO target and that it is modified by the SUMOylation
system at lysine residues 70 and 219 during viral infection (Pal 2010, Pal, Santos et al.
2011, Xu, Klenk et al. 2011, Santos, Pal et al. 2013). In addition, influenza viral infection
causes an increase in cellular SUMOylation and the appearance of novel SUMOylated
bands in a viral-replication dependent manner (Pal, Santos et al. 2011). Furthermore,
four other influenza viral proteins, PB1, NP, M1, and NEP, were shown to be
SUMOylated upon viral infection, with NS1 being the most effectively SUMOylated
protein (Pal, Santos et al. 2011, Wu, Jeng et al. 2011). Altogether, the interaction
between the viral proteins, M1 and NS1, with the SUMOylation pathway serves as a
mechanism facilitating the progression of influenza infection, further supporting the
relevance for influenza viral infection.
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1.15 Significance and Aims
Influenza virus is the etiologic agent responsible for the contagious respiratory
illness that afflicts millions of people worldwide during seasonal winter epidemics.
Current treatments against influenza A virus, such as vaccines and anti-viral drugs,
target structural components of the virus and are becoming largely ineffective due to
accumulation of mutations either through antigenic drift or antigenic shift. The sporadic
occurrence of pandemics, to which a population has little or no pre-existing immunity,
can lead to severe and even deadly respiratory infections, highlighting the need to
develop new therapeutics against influenza virus that are independent of virus strain or
subtype by targeting cellular components necessary for viral replication.
Viruses exploit host cellular systems in order to efficiently and effectively replicate
to produce new viral progeny. One of the cellular systems shown to be exploited during
viral infections is the cellular SUMOylation system. Although an interaction between the
cellular SUMOylation system and influenza virus has been identified, it is not
understood how influenza virus specifically utilizes this system during viral infection.
Elucidating the relevance of this interaction could lead to a better understanding of the
mechanisms regulating influenza viral infection and, ultimately, the development of
novel treatments to combat influenza virus.
There are three aims of this dissertation: 1) the assessment of NS1 SUMOylation
and its role during viral infection; 2) the investigation of the interplay between the
increase in cellular SUMOylation and viral infection; and 3) the evaluation of a novel
protein that could potentially act as a therapeutic agent against influenza viral infection.
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Previous studies identified eight influenza viral proteins that are SUMOylated in
vitro, of which five have been shown to be SUMOylated during viral infection (Pal,
Santos et al. 2011). Of the influenza viral proteins SUMOylated during viral infection, it
was shown that NS1 is the most effectively SUMOylated viral protein, suggesting that
SUMOylation may be playing a role in modulating NS1 function (Pal 2010). Currently,
the relevance of NS1 SUMOylation during viral infections has yet to be characterized.
Therefore, the focus of Chapter 2 is to assess the relevance of NS1 SUMOylation
during influenza viral infection in both tissue culture and animal models. Moreover, we
evaluate how mutations affecting NS1 SUMOylation affect viral fitness, clinical signs
and symptoms, and pathogenicity.
Furthermore, we have demonstrated that influenza viral infection causes an
increase in cellular SUMOylation that is neither cell specific nor strain specific (Pal,
Santos et al. 2011). Molecular studies have shown that the influenza viral protein NS1 is
the main factor responsible for this increase in cellular SUMOylation (data not
published). However, increases in cellular SUMOylation have not been characterized for
other viruses nor whether it occurs in animal infections. Therefore, the goal of Chapter
3 is to investigate whether the increase in cellular SUMOylation occurs in animal
infections or as an artifact of tissue culture infections. Moreover, whether the increase in
cellular SUMOylation is specific to influenza virus or shared among other viruses is
assessed.
Previous studies have shown that cells over expressing components of the
SUMOylation pathway, including SUMO or the conjugating enzyme, Ubc9, are less
likely to become infected with influenza virus. In addition, studies have shown that
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modulation of NS1 SUMOylation decreases NS1‘s ability to neutralize the host IFN
response. Although the development of the artificial SUMO ligase specifically enhances
the SUMOylation of NS1, its effects have yet to be tested during influenza viral infection.
Therefore, the objective of Chapter 4 is to evaluate the artificial SUMO ligase (ASL) for
its use as a novel therapeutic treatment against influenza infection.
Together, these studies provide the first conclusive evidence for the existence of
an interaction between the cellular SUMOylation system and a viral infection in an
animal model. They also show how an increase in general levels of cellular protein
SUMOylation is a phenomenon associated to infection with all viral agents tested and,
therefore, may represent a cellular response to viral infection. Importantly, for influenza
virus this is a phenomenon observed during infection in both tissue culture and animal
models. In addition, they demonstrate that the use of the artificial SUMO ligase could
potentially be an effective therapeutic against influenza viral infection.
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CHAPTER 2: MUTATIONS AFFECTING NS1 SUMOYLATION DURING INFLUENZA
VIRAL INFECTION ALTER VIRAL GROWTH AND PATHOGENICITY

2.1 Introduction:
Influenza virus is a contagious respiratory virus responsible for seasonal
epidemics and continues to be a global threat to public health. It is estimated that
influenza infections affect 5 to 20 percent of the population resulting in approximately
50,000 deaths and 2 million hospitalizations in the United States alone (Lowen,
Mubareka et al. 2007, Pillet, Kobasa et al. 2011, Fauci and Collins 2012, Maines, Belser
et al. 2012). Influenza virus can be transmitted via direct contact with infected
individuals, contact with virus-infected objects, and inhalation of infectious aerosols
(Mubareka, Lowen et al. 2009).
Upon viral infection, the virus is recognized by PRRs which will initiate a robust
host antiviral response. Viruses, as well as other pathogens, have evolved strategies to
antagonize host antiviral mechanisms (Ploegh 1998). The non-structural protein of
influenza A virus, NS1, is a multifunctional protein and acts as the main antagonist of
host immune response allowing for effective propagation of the virus (Hale, Randall et
al. 2008). The first mechanism by which NS1 subverts the immune response is by
preventing the virus-mediated activation of RIG-I, which senses double-stranded RNA
(dsRNA) within the cytoplasm (Hale, Randall et al. 2008, Meunier and von Messling
2011). NS1 sequesters dsRNA by binding RNA through residues arginine 38 and lysine
41 within the N-terminal RNA binding domain, thus preventing RIG-I activation (Hale,
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Randall et al. 2008). In addition, NS1 is able to directly interact with RIG-I through
complex formation that is stabilized by the presence of 5’-triphosphorylated single
stranded RNA (Garcia-Sastre 2011, Goubau, Deddouche et al. 2013). NS1 is also able
to block the function of two cytoplasmic antiviral proteins, PKR and OAS, which are
involved in IFN production and cellular apoptosis, respectively, by out-competing these
proteins for binding of dsRNA (Hayman, Comely et al. 2006, Kochs, Garcia-Sastre et al.
2007). Similarly, binding of dsRNA by NS1 prevents the activation of the IRF3 and 7,
NF-kB, and c-Jun/ATF-2, transcription factors responsible for the expression of type I
IFNs, (Kawai and Akira 2006, Hale, Randall et al. 2008) and interferes with the RNAsilencing antiviral response (Li, Li et al. 2004).
NS1 is also able to form an inhibitory complex with components of the cellular
mRNA nuclear export machinery, including NXF1, p15, RaeI, E1B-AP5 and Nup98
(Satterly, Tsai et al. 2007). A majority of these interactions, such as PABPI, nucleolin,
E1B-AP5, and importin-alpha occur in close proximity to NS1 residue K70. Interactions
with CrkL, PABPII, PDZ, hStaufen, and p15 occur in close proximity to K219 (Hale,
Randall et al. 2008). Studies have shown that viruses that cannot form these
interactions, contain truncated forms of NS1, or do not contain NS1, induce large
amounts of IFN during viral infection and are attenuated in IFN-competent and IFNdeficient systems (Garcia-Sastre, Durbin et al. 1998, Hale, Randall et al. 2008). We
have demonstrated, through transfection studies, that lysine to alanine mutations at
residues 70 and 219, which also results in the loss of NS1 SUMOylation, dramatically
decreases NS1’s ability to neutralize the IFN response (Santos, Pal et al. 2013).
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In addition, in vitro and in vivo methods have shown that out of all the proteins
produced by influenza virus during infection, NS1 is the most effectively SUMOylated
(Pal, Santos et al. 2011). Two SUMOylation sites have been characterized within the
influenza A/Puerto Rico/8/1934 NS1, located at lysine residues K70 and K219 (Santos,
Pal et al. 2013). The SUMOylation of NS1 is highly conserved at residues K70 and
K219 in H1N1 and H3N2 human, or low pathogenic, strains of influenza virus (Santos,
Pal et al. 2013). These same residues are not present in avian, or high pathogenic,
strains of influenza, including H5N1, H9N2, and the new H7N9 (Santos, Pal et al. 2013).
The objective of this chapter is to determine the relevance of NS1 SUMOylation and
how it contributes to the pathogenicity during influenza viral infection.
For these studies, recombinant viruses were synthesized from plasmids
encoding the influenza viral genome using an 12-plasmid based reverse genetics
system as shown in Figure 2.1 (Pekosz, He et al. 1999, Neumann and Kawaoka 2002,
Neumann, Fujii et al. 2005). In the 12-plasmid system, four of the plasmids, each
carrying one of the genes for the structural components of the viral polymerase (PB2,
PB1, PA, and NP), have an RNA polymerase II promoter, thus allowing for the
production of messenger RNA coding for those genes and the subsequent synthesis of
the encoded proteins. The remaining eight plasmids, each carrying one of the influenza
viral gene segments, under a RNA polymerase I promoter, allow for the production of
viral RNA. The viral polymerase, produced by the four RNA polymerase II plasmids, will
then initiate viral replication and transcription of the vRNA produced by the RNA
polymerase I plasmids. In the 8-plasmid system, each of the plasmids carries one
influenza viral gene segment flanked by both RNA polymerase I and RNA polymerase II
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promoters, which allow for the production of viral RNA and messenger RNA from the
same template (Neumann, Fujii et al. 2005).
Plasmids were generated containing the NS1 from Puerto Rico (PR8) influenza
strain within the A/Wilson Smith Neurotropic/1933 (WSN) gene constellation. This
substitution was made due to the strong interferon blocking ability of the PR8 NS1
(Hayman, Comely et al. 2006, Kochs, Garcia-Sastre et al. 2007, Kuo, Zhao et al. 2010).
The main SUMOylation sites within the NS1 from A/Puerto Rico/8 1934 have been
identified as lysine residues K70 and K219 (Santos, Pal et al. 2013), the latter of which
is not a SUMOylation site within WSN NS1. Table 2.1 describes each of the
recombinant viruses that were developed and the modifications that were introduced
into the plasmid that encodes the PR8 NS gene segment. A complete list of all the
plasmids developed is shown in Appendix A.
The shifted mutants were developed in order to prevent introducing an
asparagine to histidine substitution at amino acid residue 62 within NS2 when the
K219A mutation is introduced. The shifted constructs were constructed by mutating the
splicing acceptor site within the NS gene segment, followed by the introduction of a
copy of the second exon for NS2, including a functional splicing acceptor site,
downstream from the stop codon for NS1 (Figure 2.2). This construct encoded the
shifted wild-type NS gene segment used to develop the WSN/T7T7[NS1~NS2]
recombinant virus. To develop the shifted double mutant construct, two lysine to alanine
mutations were inserted at positions 70 and 219 within the NS gene segment (Figure
2.2). This construct encoded the shifted double-mutant NS gene segment used to
develop the WSN/T7T7[NS1K70AK219A~NS2] recombinant virus.
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Plasmids carrying influenza gene segments under
a PolI promoter in the reverse complementary
sense (i.e. coding for vRNA)
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Figure 2.1. Diagram of the 12-plasmid based reverse genetics system. Full length
cDNAs of the eight gene segments were cloned into RNA polymerase I (Pol I) based
plasmids. In addition, full length cDNAs expressing PA, PB1, PB2 and NP gene
segments, which are required for transcription and replication of vRNAs, were cloned
into Pol II based plasmids. The 12 plasmids are then co-transfected allowing for the
production of replication competent viral particles.
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Table 2.1 Properties of the recombinant viruses developed and their modifications
Gene
constellation

NS gene
segment

T7T7 tag

Other modifications

1. WSN/NS

WSN

WSN

No

none

2. WSN/T7T7NS

WSN

PR8

Yes

none

3. WSN/T7T7[NS1K70AK219A]

WSN

PR8

Yes

SUMOylation deficient

4. WSN/T7T7[NS1~NS2]

WSN

PR8

Yes

Shifted NS2

5. WSN/T7T7[NS1K70AK219A~NS2]

WSN

PR8

Yes

Shifted NS2; SUMOylation
deficient

Recombinant viruses
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Figure 2.2. Generation of shifted NS constructs. The shifted constructs were
developed: 1) identification of the splicing donor (SD) and splicing acceptor (SA) sites
for NS2; 2) mutation of the splicing acceptor site alleviating the overlap of the NS1
and NS2 ORFs and preventing NS2 production; and 3) cloning of the NS2 ORF
downstream of the NS1 stop codon, including the splicing acceptor site. ORF: open
reading frame.
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2.2 Materials and Methods:
Cells and viruses
HEK293FT cells (Invitrogen Corp., Carlsbad, CA), MDCK cells (ATCC, Manassas, VA)
and VERO cells (ATCC) were maintained in complete medium consisting of 1x
Dulbecco’s modified eagle medium (DMEM) supplemented with high glucose, Lglutamine, sodium pyruvate (Corning Incorporated Life Sciences, Corning, NY), and
10% fetal bovine serum (Atlanta Biologicals, Inc., Flowery Branch, GA). For HEK293FT
cells, Geneticin (Invitrogen Corp.) was added to the complete medium at a final
concentration of 500 µg/mL. All cell lines were maintained at 37°C incubator at 5% CO2.
Influenza A/Puerto Rico/8/1934 H1N1 (referred to as PR8) was a gift from John M.
Quarles (Department of Microbial and Molecular Pathogenesis, College of Medicine,
Texas A&M Health Sciences Center). PR8 virus was propagated in MDCK cells at a
multiplicity of infection (MOI) of 0.001 by using 1x DMEM supplemented with 0.2%
bovine serum albumin (BSA) and 2 µg/mL tosyl-phenylalanyl-chloromethyl-ketone
(TPCK)-treated trypsin (Worthington Biochemical Corp., Lakewood, NJ).

Plasmids
The recombinant influenza viruses used in this study were generated as previously
described (Santos, Pal et al. 2013). In brief, the A/WSN/1933 [H1N1] 12-plasmid
reverse genetics system (Neumann, Watanabe et al. 1999) was provided by Yoshihiro
Kawaoka (Department of Pathobiological Sciences, School of Veterinary Medicine,
University of Wisconsin-Madison, Madison, WI). A double T7-tag insert was inserted at
the N-terminus of the NS1 open reading frame of our laboratory strain of A/Puerto Rico/
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8/1934 [H1N1] by using the Phusion site-directed mutagenesis kit (Finnzymes, Woburn,
MA) according to the manufacturer’s protocol. Specific mutations in the sequence of
NS1 were inserted by using the same site-directed mutagenesis approach, resulting in
the expression constructs for T7T7[NS1K70A], T7T7[NS1K219A], and the double
mutant T7T7[NS1K70AK219A]. To generate the pPol1/WSN/T7T7NS1 construct, the
pPol1/WSN/NS construct from the 12-plasmid reverse genetics system (Neumann,
Watanabe et al. 1999) was PCR amplified using primers complementary to the 5’
untranslated region (UTR) and the 3’ UTR of the WSN NS gene segment, producing a
PCR product containing the backbone of the original plasmid, and the 5’ and 3’ UTRs of
the NS gene segment from our PR8 strain. This PCR product was ligated with the PCRamplified coding region of the NS gene segment from the PR8 strain. Similar overall
approaches were used to mutate the splicing acceptor site in the NS gene segment and
generate the splicing-deficient pPol1/WSN/T7T7NS1-derived mutants, pPol1/WSN/
T7T7[NS1-SplAccptMut] and pPol1/WSN/T7T7[NS1K70AK219A-SplAccptMut], and
their NS2-shifted derivative constructs pPol1/WSN/T7T7[NS1~NS2] and pPol1/WSN/
T7T7[NS1K70AK219A~NS2].

Transient transfections and generation of recombinant viruses by reverse genetics
HEK293FT cells (Invitrogen Corp.) were seeded at a density of 5 x 105 cells/well into 6
well plates. The following day, cells were transfected by liposome-mediated transfection
using 13 µg of CsCl-purified plasmids and 26 µL of TransIT-LT1 (Mirus Bio LLC,
Madison, WI) per well, according to the manufacturer’s recommendations. Cells were
incubated at 37ºC in 5% CO2 for 24 hours. The culture supernatant was then discarded
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and replaced with 1x DMEM supplemented with 0.2% BSA and 2 µg/mL TPCK-treated
trypsin. The cells were further incubated for another 48 hours at 37ºC in 5% CO2, and
the culture supernatants were subsequently collected and used for plaque assays.

Plaque assays
MDCK cells were plated into 6-well plates at a density of 1 x 106 cells/well in 1x DMEM
supplemented with 10% fetal bovine serum (Atlanta Biologicals) and incubated at 37°C
in 5% CO2 until the cells formed a confluent monolayer. The cells were then washed
twice with 1x DMEM, and a virus dilution prepared in 1ml of 1x DMEM supplemented
with 0.2% BSA was added to the cells and incubated with the cells at 35°C for 1 hour.
The supernatant was removed and a 3-mL overlay of 1x DMEM supplemented with
TPCK-treated trypsin (at a final concentration of 1%) and 0.6% SeaKem ME agarose
(Lonza, Rockland, ME), maintained at 39.5°C using a bench-top heater-shaker, was
poured over the cells and allowed to solidify for 20 minutes at room temperature. The
cells were subsequently incubated at 35°C in 5% CO2, and starting at 24 hours postinfection, the cells were visually screened for the presence of plaques. When the size of
the plaques observed reached 1 to 2 mm in diameter, the overlay was removed, and the
cells were fixed and stained with a solution containing 0.12% crystal violet in 20%
ethanol.
Alternatively, for plaque purification of recombinant viruses, the overlay was left in
place, and well-isolated plaques were transferred into a vial containing 1x DMEM plus
0.2% BSA by using a sterile 1-mL pipette. All of the viruses produced were purified by
two consecutive rounds of plaque purification. During the second round of purification,
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plaques of identical diameter (as measured under a microscope) were selected as a
method to initiate the experiment with similar virus numbers. The plaques selected were
incubated in 1 mL of 1x DMEM plus 0.2% BSA at 4ºC for 4 hours to allow the virus to
diffuse out of the the agarose plug. Subsequently, the whole volume of 1x DMEM plus
0.2% BSA, including the agarose plug, was added to a confluent monolayer of MDCK
cells or Vero cells plated onto 10 cm3 petri dishes in 1x DMEM supplemented with 0.2%
BSA and TPCK-treated trypsin at a final concentration of 1%. At 24 and 48 hours postinfection, the culture supernatants were removed, and their virus titers were analyzed by
plaque assay.

Animal infections
All animal experiments were approved by the institutional animal care and use
committee of the University of Maryland-College Park, Department of Veterinary
Medicine. Female, 6-week-old DBA/2J mice (The Jackson Laboratory, Bar Harbor, ME)
were used for viral pathogenicity experiments. Mice were anesthetized in groups of five
by isoflurane inhalation and infected intranasally with 1x105 PFU of the respective virus
in 50 µL of PBS. To determine differences between clinical signs of disease, a 0-1-2-3
scoring scale was used, with 0 and 3 representing normal and severe, respectively
(Koudstaal, Koldijk et al. 2009). Animals were observed for 6 days for clinical signs of
infection. Viral pathogenicity (viral titers and gross and histopathology) was studied in
two groups of twenty mice over 6 days. Four mice from each group were sacrificed on
days 0, 1, 2, 4, and 6 after inoculation and lungs, trachea, nasal turbinates, kidney, and
brain were removed from each mouse and immediately stored at -80°C in PBS.
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TCID50 to determine viral titers
MDCK cells were plated into 96-well plates at a density of 1.6 x 105 cells/well in 1x
DMEM supplemented with 10% FBS and incubated at 37°C in 5% CO2 until the cells
formed a confluent monolayer. The cells were then washed once with 1x DMEM, and a
virus dilution prepared in 1ml of 1x DMEM supplemented with 0.2% BSA was added to
the cells and incubated with the cells at 37°C in 5% CO2 for 3 days until cytopathic
effects (CPE) were observed. 50 µL of the supernantants from TCID50 plates were
transferred to a 96-well V-bottom plate (Corning Incorporated Life Sciences). 50 µL of
0.5% turkey red blood cells (Lampire Biological Laboratories, Pipersville, PA)
suspended in 1x PBS, were added to the V-bottom plate and gently tapped to mix.
Plates were incubated at room temperature for 45 minutes. Plates were scored and viral
titers were determined using the Reed-Muench method.

Histology
A portion corresponding to approximately 10% of lung tissue from mice at days 4 and 6
post-inoculation were dissected, washed in sterile PBS, and fixed in 10% neutral
phosphate buffered formalin (NBF). Tissue samples were embedded in paraffin, cut into
5-µm-thick sections, and stained with hematoxylin and eosin (H&E) for histopathological
examination or were processed for analysis by immunohistochemistry.

Viral titration and viral RNA sequencing
A confluent 96-well tissue culture plate of MDCK cells was prepared one day before the
virus titration. Virus was titrated in lungs, trachea, nasal turbinates, kidney, and brain.
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Tissues were homogenized in PBS using a bead mill homogenizer (Tissue Lyser,
Qiagen, Valencia, CA). Cell debris was pelleted by centrifugation and supernatant was
titrated on MDCK cells. Cells were washed once with PBS and serial dilutions were
performed (from 1 log10 to 10 log10 dilutions) in serum-free 1x DMEM medium
supplemented with 1% penicillin/streptomycin (Corning Incorporated Life Sciences) and
1% TPCK-treated trypsin (Sigma, Oakville, ON). Viral dilutions were added onto the
plates and at 72 hours post-infection the plates were scored for cytopathic effect. 50 µL
of the supernantants from TCID50 plates were transferred to a 96-well V-bottom plate
(Corning Incorporated Life Sciences). 50 µL of 0.5% turkey red blood cells (Lampire
Biological Laboratories) suspended in 1x PBS, were added to the V-bottom plate and
gently tapped to mix. Plates were incubated at room temperature for 45 minutes. Titers
were expressed as 50% tissue culture infectious dose (TCID50) per mL using the ReedMuench Method.
Total RNA was extracted using the RNeasy Mini Kit (Qiagen). A reverse
transcription product of the viral RNA was generated using the M-MLV Reverse
Transcriptase (Promega, Madison, WI) and using the previously described UNI-12
primer (Hoffmann, Stech et al. 2001) targeting the 12 conserved nucleotides at the 3’
end of all viral RNA gene segments. A secondary set of primers were used to target the
amplification of the NS gene segment through the generation of two overlapping readouts.
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Immunoblot analyses
Prior to SDS-PAGE analyses, all cell extracts generate were passed several times
through a 29½ gauge needle to break down the genomic DNA released and to decrease
the viscosity of the samples. β-mercaptoethanol was added up to a final concentration
of 10%, and the samples were boiled in a water bath for 3 minutes. The samples were
resolved by 10% SDS-PAGE gels made in-house and, subsequently, the proteins were
transferred to Immobilon-FL (Millipore Corp., Bedford, MA) for use with IRDyeconjugated secondary antibodies (LI-COR Biosciences Inc., Lincoln, NE) and infrared
fluorescence imaging.

Infrared fluorescence imaging
Immobilon-FL membranes (Millipore Corp.) were washed four times in 1x PBS, blocked
with Odyssey Blocking Buffer (LI-COR Biosciences Inc.) for a minimum of 1 hour at
room temperature, and incubated in Odyssey Blocking Buffer at 4°C overnight with the
primary antibody at the indicated dilution. The membranes were then washed four times
with 1x PBS, supplemented with 0.1% polysorbate 20 (Tween 20), and incubated with
Odyssey Blocking Buffer with the appropriate highly cross-absorbed IRDye 800 CWand IRDye 680 LT-conjugated secondary antibodies (LI-COR Biosciences Inc.) at the
indicated dilution. The membranes were then washed four times with 1x PBS,
supplemented with 0.1% Tween 20 and twice again with 1x PBS and scanned on an
Odyssey CLx infrared imaging system (LI-COR Biosciences Inc.). Quantitative analyses
of the images obtained was performed by using Odyssey Infrared Imaging System
Application software version 3.0.29 (LI-COR Biosciences Inc.). Statistical analyses and
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graphics of the data generated were performed by using GraphPad Prism version 5.04
for Windows (GraphPad Software Inc., San Diego, CA).

Immunohistochemistry
Approximately 10% of lung tissue from mice at days 4 and 6 post-inoculation were
dissected, washed in sterile PBS, and fixed in 10% NBF. Tissue sample were
embedded in paraffin, cut into 5-um-thick sections, and mounted onto glass slides.
Paraffin was removed using two washes of xylene followed by ethanol gradient (100%,
95%, and 80%) washes. A 70% ethanol wash was supplemented with 0.25% ammonia
and incubated for 1 hour at room temperature. Slides were incubated in 50% ethanol
followed by two washes in 1x PBS to rehydrate the tissues. Antigens within the tissues
were unmasked by incubating in 1 mM ethylenediaminetetraacetic acid (EDTA) and
heated in a microwave on full power until the buffer began to boil. The tissues were let
cool for 20 minutes and washed three times with 1x PBS, the last of which was
supplemented with sodium borohydride (Sigma Aldrich, St. Louis, MO) at a
concentration of 10 mg/mL, to minimize the autofluorescence of the tissues, and
followed by four washes with 1x PBS.
Tissue sections were drained and a hydrophobic barrier was drawn around each
tissue using an ImmEdge Pen (Vector Laboratories, Burlingame, CA). In order to
permeabilize the tissues, the sections were washed twice with 1x PBS, the second of
which was supplemented with 0.2% Triton X-100 (MP Biomedicals, Santa Ana, CA), and
followed by three washes with 1x PBS. Sections were blocked with 1x PBS with 1%
goat serum for 1 hour at room temperature and incubated in 1x PBS with 1% goat
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serum at 4C overnight with the primary antibody at the indicated dilution. The sections
were then washed four times with 1x PBS and incubated with 1x PBS with 1% goat
serum supplemented with the appropriate highly cross-absorbed AlexaFluor 594 and
488 fluorophore conjugated secondary antibodies (Life Technologies Inc.) at the
indicated dilution. Sections were washed three times in 1x PBS followed by one wash
with 1x PBS supplemented with 4’,6-diamidino-2-phenylindole, dihydrochloride (DAPI)
(Thermo Scientific) at a final concentration of 0.5 ug/mL. Sections were washed in 1x
PBS, glycerol and glass cover slips were added, and slides were sealed with clear nail
polish.

Statistical analysis and computer software.
All statistical analyses and graphics presented were performed by using GraphPad
Prism version 5.04 for Windows (GraphPad Software Inc.). All figures were created by
using Adobe Photoshop CS5 extended version 12.0.3 X64 (Adobe Systems Inc., San
Jose, CA).
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2.3 Results:
NS1 SUMOylation affects viral growth in IFN-competent and IFN-deficient
host cells. Previous studies had shown that out of all the viral proteins produced during
influenza viral infections, the NS1 protein was the most extensively SUMOylated protein
(Pal, Santos et al. 2011). To determine the effect of NS1 SUMOylation on viral
infection, recombinant viruses containing either a SUMOylatable NS1 (referred to as
WSN/T7T7[NS1~NS2]) or a non-SUMOylatable NS1 (referred to as WSN/T7T7[NS1
K70AK219A~NS2]) were used to infect MDCK cells. Infection with the WSN/
T7T7[NS1~NS2] virus produced viral titers in the 1-3 x 107 PFU/mL range in MDCK
cells 24 hours post-infection (hpi). Infection with the WSN/T7T7[NS1K70AK219A~NS2]
virus produced significantly lower viral titers of 3.5 x 103 PFU/mL, approximately 2.5logs lower than titers obtained after infection with the WSN/T7T7[NS1~NS2] virus
(Figure 2.3A). At 48 hpi, infection with the WSN/T7T7[NS1K70AK219A~NS2] virus
resulted in slightly lower titers than infection with the WSN/T7T7[NS1~NS2] virus. To
determine if this difference was due to an alteration of NS1‘s ability to neutralize the IFN
response, we used the same recombinant viruses to infect Vero cells, which are
incapable of producing type-1 IFN (Figure 2.3B). Infection with the WSN/
T7T7[NS1~NS2] virus produced viral titers in the 2-5 x 104 PFU/mL range 24 hpi and
0.7-1.1 x 106 PFU/mL at 48 hpi. Infection with the WSN/T7T7[NS1K70A K219A~NS2]
virus resulted in significantly lower viral titers of 2.3 x 102 PFU/mL at 24 hpi, and
appeared to have stopped growing, as the titers appear similar at 48 hpi (Figure 2.3B).
In addition, during the plaque purification steps we observed that plaque formation by
the WSN/T7T7[NS1K70AK219A~NS2] virus resulted in dramatically smaller plaques
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than plaques produced by the WSN/T7T7[NS1~NS2] virus (Figure 2.3C). When the
differences were quantified, plaques resulting from infection with the WSN/T7T7[NS1
K70AK219A~NS2] virus were approximately 2.5 times smaller than those that formed
from infection with the WSN/T7T7[NS1~NS2] virus (Figure 2.3D).

Infection with an influenza viral mutant expressing a non-SUMOylatable
PR8 NS1 results in an increase in clinical symptoms, morbidity, and mortality in
the mouse model. Due to the differences in viral titers between viruses containing a
SUMOylatable and non-SUMOylatable NS1, we sought to determine the effect of NS1
SUMOylation in an animal model. The overall approach for this experiment is shown in
Figure 2.4. Each infected mouse was assigned an average clinical score associated to
viral infection ranging from 0 to 3, with 0 being normal and 3 being the lethal endpoint
required by the IACUC protocol. At days 0, 1, and 2 all mice were assigned a clinical
score of 0 indicating no signs of infection and/or normality (Figure 2.5A). At day 4 postinfection, mice infected with the either virus showed an increase of average clinical
score to 1, characterized by weight loss and lack of grooming. By day 6 post-infection,
the mice infected with the WSN/T7T7[NS1~NS2] virus were assigned an average
clinical score of 2, characterized by further weight loss, between 10-20%, rough coat,
and reduced motility. Mice infected with the WSN/T7T7[NS1K70AK219A~NS2] virus
were assigned an average clinical score of 3, characterized by even further weight loss,
a very rough coat, immobility, and abnormal posture (Figure 2.5A). In addition to
exacerbated clinical symptoms, infection with the WSN/T7T7[NS1K70AK219A~NS2]
virus was also associated with increased average weight loss beginning 2 days post58

infection (p.i.) (Figure 2.5B). Interestingly, mice infected with the WSN/T7T7[NS1~NS2]
recombinant virus gained weight at day 2 post-infection, followed by significant weight
loss by day 4 post-infection (Figure 2.5B). On the contrary, mice infected with the WSN/
T7T7[NS1K70AK219A~NS2] recombinant virus showed consistent weight loss over the
6 days post-infection (Figure 2.5B). The mortality rate was also slightly higher in the
WSN/T7T7[NS1K70AK219A~NS2] infected mice, resulting in three deaths, and the
WSN/T7T7[NS1~NS2] infection resulting in only one death (Figure 2.5B).

Infection with an influenza viral mutant expressing a non-SUMOylatable
PR8 NS1 also results in viral detection in a broader range of organs. To determine
differences in viral replication in an animal model, we assessed viral titers at day 1, 2, 4,
and 6 post-infection. The recombinant virus containing a non-SUMOylatable form of
NS1 produced viral titers similar to the recombinant viruses containing a SUMOylatable
form of NS1 in the lungs, trachea and nasal turbinates at days 1, 2, 4, and 6 postinfection (Figure 2.6A-C). Viruses were detected in the kidney (Figure 2.6D) and brain
(Figure 2.6E) day 6 post-infection, with viral titers of 8.4 x 102 and 1.0 x 102 TCID50/mL,
respectively, in mice infected with the WSN/T7T7[NS1K70AK219A~NS2] virus, while no
viruses were detected in those organs in mice infected with the WSN/T7T7[NS1~NS2]
virus.
In order to verify that the data collected during viral infection could be attributed
to the presence of the indicated mutations known to prevent NS1 SUMOylation, total
RNA was isolated from the lungs collected at days 1, 2, 4, and 6 post-infection from four
mice per group. The NS gene segment was amplified by RT-PCR and the resulting
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cDNA was sequenced using a series of sequencing primers designed to generate
overlapping read outs. The chromatograms obtained indicated that some of the samples
analyzed consisted of a diverse population of viruses that frequently carried mutations
different from these initially introduced at codons 70 and 219 of NS1, as indicated by the
overlapping peaks shown for the sequences derived around codons 70 and 219 for all
the WSN/T7T7[NS1K70AK219A~NS2] infected animals (Figure 2.7). Although the viral
population was mixed, the predominant peaks in the chromatogram represent
nucleotides that would encode for either an alanine or a glutamic acid at residues 70
and 219 (Figure 2.7), two amino acid substitutions that still render NS1 nonSUMOylatable.

Infection with a recombinant virus expressing a non-SUMOylatable PR8
NS1 results in increased gross pathology and enhanced histopathological
changes in the lung. Since the severity of influenza infection is frequently associated
to the degree of lung damage produced, lungs harvested from WSN/T7T7[NS1~NS2]
and WSN/T7T7[NS1K70AK219A~NS2] infected mice were evaluated for gross
pathology and histopathology. In the first two days of infection, there was no change in
the overall activity of the mice or the gross pathology of the lungs (data not shown).
Beginning at day 4 post-infection, we observed that lungs harvested from both groups of
infected mice displayed lung enlargement and the development of pulmonary
hemorrhages (Figure 2.8A). More evident pathological changes were observed at day 6
post-infection in both groups of infected mice with the development of plum-colored
pulmonary lesions, which sharply contrasted with the pink-colored lungs of non-infected
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(healthy) mice (Figure 2.9A). Remarkably, the lesions observed in mice infected with
the WSN/T7T7[NS1K70AK219A~NS2] virus were substantially more severe than those
observed for mice infected with the WSN/T7T7[NS1~NS2] virus (Figure 2.9A), with
lungs of WSN/T7T7[NS1K70AK219A~NS2] infected mice exhibiting complete
hemorrhaging of the lungs and little to no visible pink-colored tissue.
To further examine the significance of NS1 SUMOylation on influenza viral
infection, we evaluated histopathological changes in lung tissue from infected mice at
days 4 and 6 post-infection (Figure 2.8B and Figure 2.9B). Viral infection with either
WSN/T7T7[NS1~NS2] or WSN/T7T7[NS1K70AK219A~NS2] resulted in significant
changes in lung architecture as compared to lung tissue from day 0 post-infection
(Figure 2.8B and 2.9B). Infected lung tissue from WSN/T7T7[NS1~NS2] infected mice
displayed severe bronchiolar hyperplasia 6 days post-infection (Figure 2.9B). In
addition to bronchiolar hyperplasia, the WSN/T7T7[NS1K70AK219A~NS2] infected lung
tissue also displayed epithelial necrosis with a complete loss of the epithelium (Figure
2.9B).
Microscopically, histopathological changes in all infected animals were
characterized by moderate to severe bronchiolar lesions including necrosis, infiltration
of cell debris, and epithelial hyperplasia (Table 3). Mice infected with the WSN/
T7T7[NS1~NS2] virus exhibited mild to moderate alveolar lesions caused by the
infiltration of inflammatory cells (Table 3). In contrast, mice infected with the WSN/
T7T7[NS1K70AK219A~NS2] virus produced moderate to severe lesions which were
further characterized by diffuse alveolar damage and the development of hyaline
membranes. Mild vascular lesions were observed in both groups and were attributed to
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perivascular cuffing with lymphocytes and occasional vasculitis (Table 3). The total lung
scores for mice infected with the WSN/T7T7[NS1K70AK219A~NS2] virus were slightly
higher than those from mice infected with the WSN/T7T7[NS1~NS2] virus.
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Figure 2.3. Mutations affecting NS1 SUMOylation decreases viral fitness in
tissue culture. Viral growth of the recombinant viruses developed with the various
pPolI/WSN/NS gene segments. All recombinant viruses generated by reverse
genetics, including WSN/T7T7[NS1~NS2] and WSN/T7T7[NS1K70AK219A~NS2],
were purified by two consecutive rounds of plaque purification. Plaques of identical
diameter produced during the second round of plaque purification were inoculated
over a confluent monolayer of either MDCK cells or Vero cells plated on 10 cm
petri dishes. Twenty four and forty-eight hours post-infection the culture
supernatants were removed and their viral titers analyzed by plaque assay. (A)
Viral titers obtained with the supernatants collected from MDCK cells. (B) Viral
titers obtained with the supernatants collected from Vero cells. (C) Representative
plaques showing resulting plaque morphology. (D) Diameter of resulting
plaques. The values presented in B correspond to the data obtained from the
random sampling of 10 plaques. The values presented in C and D corresponds to
the data obtained in 3 independent experiments. Error bars indicate standard
deviation. *, P < 0.05. ***, P < 0.0001.
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Figure 2.4. Overall experimental approach. 5-6 week old female DBA/2J mice were
inoculated with one of the viruses indicated. At the indicated times post-infection, four
animals per inoculation group were sacrificed and the organs were harvested for viral
multiplication analysis and vRNA sequencing.
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Figure 2.5. Impairment of NS1 SUMOylation does not affect survival but causes
increased weight loss during viral infection in vivo. (A) Average clinical score of
animals infected with either WSN/T7T7[NS1~NS2] or WSN/T7T7[NS1K70A K219A~
NS2]. (B) Average weight loss of animals infected with either WSN/T7T7[NS1~NS2] or
WSN/T7T7[NS1K70AK219A]~NS2.
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Figure 2.6. Impairment of NS1 SUMOylation results in viral detection in a
broad range of organs. Viral titers of tissues from mice infected with either WSN/
T7T7[NS1~NS2] or WSN/T7T7[NS1K70AK219A]~NS2. (A) Viral titers in lungs. (B)
Viral titers in trachea. (C) Viral titers in nasal turbinates. (D) Viral titers in kidney. (E)
Viral titers in brain. Error bars indicate standard deviation. ***, P<0.0001.
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Figure 2.7. Viral replication in vivo results in a mixed population of viruses.
Sequencing results of WSN/T7T7[NS1K70AK219A~NS2] viruses collected at 1, 2,
4, and 6 days post-infection.
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Figure 2.8. Viruses containing a non-SUMOylatable NS1 significantly enhance
changes in gross pathology and histopathology in lungs from infected mice at
4 days post-infection. (A) Gross pathology of the lung after infection in a mockinfected control (top) or after infection with WSN/T7T7[NS1~NS2] (middle) or
WSNT7T7[NS1K70AK219A ~NS2] (bottom) viruses. Mice were inoculated as
described in Figure 1 legend and lungs harvested at day 4 post-infection. (B) Lungs
were fixed in formalin, embedded in paraffin, sectioned, and mounted onto glass
slides. Haematoxylin and eosin-stained sections of lung tissue from mice infected
with recombinant viruses and sacrificed at day 4 post-infection. Images are shown
at 200x magnification.
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Figure 2.9. Viruses containing a non-SUMOylatable NS1 significantly enhance
changes in gross pathology and histopathology in lungs from infected mice at
6 days post-infection. (A) Gross pathology of the lung after infection in a mockinfected control (top) or after infection with WSN/T7T7[NS1~NS2] (middle) or
WSNT7T7[NS1K70AK219A~NS2] (bottom) viruses. Mice were inoculated as
described in Figure 1 legend and lungs harvested at day 6 post-infection. (B) Lungs
were fixed in formalin, embedded in paraffin, sectioned, and mounted onto glass
slides. Haematoxylin and eosin-stained sections of lung tissue from mice infected
with recombinant viruses and sacrificed at day 6 post-infection. Images are shown
at 400x magnification.
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Table 2.2 Pathology report from influenza infected lungs

70

2.4 Discussion:
Previous studies relating to the role of SUMOylation for the influenza virus nonstructural protein NS1 had suggested a role for regulating the function of NS1 through
the modulation of protein-protein interactions, thus limiting its ability to neutralize the
host antiviral response (Santos, Pal et al. 2013). Despite the ongoing research related
to the role of NS1 SUMOylation in tissue culture, this is the first and only study that
investigates the role of SUMOylation of a viral protein in an animal model. Here, we
evaluated the effects of mutations affecting NS1‘s ability to become SUMOylated in a
mouse model of influenza infection. We demonstrated that compared with a virus
carrying a SUMOylatable NS1 protein, infection with viruses containing a nonSUMOylatable NS1 resulted in increased clinical symptoms, morbidity, and mortality.
Furthermore, the inhibition of NS1 SUMOylation enabled viral detection in a broad
range of organs and increased the pathology of influenza viral infection. Overall, our
results indicate that a non-SUMOylatable PR8 NS1 exhibits increased pathogenicity as
compared to its SUMOylated counterpart.
In addition to the viral proteins HA, NA, PB2, and PB1-F2, NS1 has also been
implicated as a pathogenicity factor for influenza viral infections (Hale, Randall et al.
2008, Tscherne and Garcia-Sastre 2011). Certain characteristics within NS1, such as
glycine residue 184 (Steidle, Martinez-Sobrido et al. 2010) and the four C-terminal
residues (Jackson, Hossain et al. 2008) have been identified as determinants for
influenza virulence. Due to the increase in pathogenicity observed with the mutant virus,
this study provides the first insight on whether the ability of NS1 to be SUMOylated may
act as a good predictor of viral pathogenicity. Further studies would need to be
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performed to determine whether these findings would be applicable to other influenza
viral strains. Similar to the results using viruses containing a non-SUMOylatable M1
obtained by Wu, et al. (Wu, Jeng et al. 2011), tissue culture studies using viruses
containing a non-SUMOylatable NS1 showed impaired viral growth (Santos, Pal et al.
2013). However, in these animal studies, there was no significant difference in viral
titers between the wild-type and mutant virus in the lung, trachea or nasal turbinates
over the course of viral infection.
Furthermore, in a study by Xu, et al. (Xu, Zhong et al. 2013), lysine residue 70
has been found to form hydrogen bonds with RNA, directly and indirectly, via water
suggesting that K70 may play a role in RNA-dependent interactions. It is possible that
the non-SUMOylatable NS1 may be able to bind double-stranded RNA more effectively,
which has been shown to lead to a strong, prolonged activation of inflammatory
cytokines and the innate immune response, as well as, an increase in the rate of viral
replication (Kurokawa, Koyama et al. 1999). The sustained increase in the immune
response, along with enhanced viral replication, leads to more severe pathology as
observed in infections with highly pathogenic strains of influenza virus (Baskin,
Bielefeldt-Ohmann et al. 2009). However, the SUMOylation of NS1 may alter its ability
to bind double-stranded RNA resulting in the activation and induction of genes relevant
to the IFN response and the innate immune and stress pathways in order to overcome
viral infection. SUMOylation of NS1 may also serve as a docking site for additional
protein-protein interactions regulating these responses. The balance between the
immune response and stress response allows for the slower replication of the viruses
resulting in lower pathogenicity and less severe pathology.
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In contrast to studies performed in tissue culture showing that viruses containing
a non-SUMOylatable NS1 had decreased viral growth as compared to viruses
containing a SUMOylatable NS1, studies performed in an animal model showed that
viruses containing a non-SUMOylatable NS1 developed more severe pathology
associated to viral infection. These contrasting results may be attributed to differences
in the viruses ability to overcome the cellular immune and stress responses. It is likely
that SUMOylation of NS1 is required for other functions associated to viral infection in
tissue culture, however are dispensable during infections in an animal model.
Furthermore, a previous study found that influenza A virus grows at a slower rate in
Vero cells as compared to MDCK cells (Youil, Su et al. 2004), so these differences may
have been exacerbated during viral infection in Vero cells resulting in lower titers.
Overall, these studies suggest that SUMOylation of viral proteins may serve as
another antiviral strategy exerted by the host in order to combat viral infection. Further
studies would be required to determine the relevance of SUMOylation for other viral
proteins and the role of SUMOylation on NS1 proteins from different strains of influenza.
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CHAPTER 3: SUMOYLATION OF VIRAL PROTEINS RESULTS IN AN INCREASE IN
CELLULAR SUMOYLATION OF INFECTED CELLS

3.1 Introduction:
Our lab has shown that NS1 is a major contributor to the global increase in
cellular SUMOylation observed during viral infection (Chacon et al., manuscript in
preparation). In addition, the increase has been characterized to occur in cells that
surround infected cells (unpublished data), and not limited to infected cells. Previous
studies by others had demonstrated that various conditions known to produce cellular
stress led to a simultaneous global increase in cellular SUMOylation in order to protect
the cell from the effects of various types of stress, including heat shock (Flotho and
Melchior 2013) and oxidative stress (Yang, Sheng et al. 2008). The upregulation of
these pathways can lead to the enhancement of SUMO-dependent protein-protein
interactions and the competitive conjugation, between SUMO and Ubc9, at specific
lysine residues (Wilson 2012).
It has been shown that both, RIG-I and MDA-5, are SUMOylated thus enhancing
their interactions with VISA, an adapter protein required for IFN signaling (Xu, Wang et
al. 2005, Wilson 2012, Liu, Wang et al. 2013). The SUMOylation of RIG-I and MDA-5
acts as a positive regulator increasing the IFN levels within the cell (Wilson 2012). Viral
infection results in the activation of TLR and RIG-I signaling pathways leading to the
phosphorylation, and subsequent SUMOylation, of IRF3 and IRF7 in a TLR/RIG-I
activation-dependent manner, however, not an IFN-dependent manner (Kubota,
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Matsuoka et al. 2008, Wilson 2012, Liu, Wang et al. 2013). The SUMOylation of IRF3
has negative effects on IFN transcription and may function by recruiting histone
deacetylases (HDACs) to the IFN promoter (Kubota, Matsuoka et al. 2008). Similarly,
the SUMOylation of IRF7 acts to repress transcription, while ubquitination of IRF7 acts
to activate transcription (Kubota, Matsuoka et al. 2008). SUMOylated transcription
factors, such as Elk1, act as transcriptional repressors by binding HDAC2 and reducing
the acetylation of chromatin (Gill 2005, Kubota, Matsuoka et al. 2008).
In addition, p300 is SUMOylated through the CRD1 domain and binds HDAC6
resulting in transcriptional repression (Gill 2005, Kubota, Matsuoka et al. 2008).
Components of the AP-1 transcription complex are targets for SUMOylation (Kubota,
Matsuoka et al. 2008). Two proteins belonging to the AP-1 complex, c-Jun and c-Fos,
are SUMOylated resulting in diminished transcriptional activity (Yang, Sheng et al.
2008). SUMOylation competes for the modification of both c-Fos and p53 (Kubota,
Matsuoka et al. 2008). The post-translational modification of p53 promotes its nuclear
export and regulates its transcriptional activity leading to G1 cell cycle arrest (Shen,
Wang et al. 2009, Bennett, Pan et al. 2012, Santiago, Li et al. 2013). Furthermore,
SUMOylation can alter through the transcriptional repression caused by the subnuclear
localization of transcription factors Sp3 and SATB2 (Kubota, Matsuoka et al. 2008).
Together, SUMOylation leads to transcriptional repression and the induction of IFN
pathways to protect the cell against stress-mediated effects.
Viral infection also leads to the activation of SUMO E3 ligases which regulate
innate immunity pathways, including JAK/STAT and NF-kB dependent transcription
(Kubota, Matsuoka et al. 2008). For example, the transcription factor, IRF1, is
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SUMOylated through induction by the E3 ligase PIAS3 (Kubota, Matsuoka et al. 2008).
The SUMOylation of STAT1 protects cells from hyper-responsiveness to IFN-gamma
thus preventing apoptosis (Song, Bhattacharya et al. 2006, Begitt, Droescher et al.
2011). PIAS3 is also responsible for the SUMOylation of the progesterone receptor
isoform B which promotes its nuclear export (Man, Li et al. 2006). Competitive
SUMOylation of IkB-alpha blocks its ubiquitination and degradation, thus preventing
activation of NF-kB (Kubota, Matsuoka et al. 2008, Yang, Sheng et al. 2008, Liu, Wang
et al. 2013). Other target proteins, such as HSF1, HSF4b, and GATA-1, must be
phosphorylated in order for them to be SUMOylated (Kubota, Matsuoka et al. 2008,
Flotho and Melchior 2013).
Many viruses use the SUMOylation system to regulate transcriptional activity,
PML-NB dispersion, cell cycle regulation and apoptosis, reactivation of latent infections,
IFN inhibition, and viral assembly (Mattoscio, Segre et al. 2013). The localization of
Sp100 and Daxx require SUMOylation for the localization and assembly in PML-NBs in
response to IFN stimulation and viral infection (Everett, Boutell et al. 2013, Glass and
Everett 2013, Mattoscio, Segre et al. 2013). Influenza infection induces activation of
PKR and IFN resulting in the accumulation of viral RNA-induced stress granules
(Onomoto, Jogi et al. 2012). In turn, the induction in IFN increases the levels of dsRNAdependent PKR within the cell (Onomoto, Jogi et al. 2012). The stress granules are
formed in a PKR-dependent manner and are comprised of viral ribonucleoprotein
complexes in which RLRs, MDA5, and LGP2 are recruited (Onomoto, Jogi et al. 2012).
The stress granules are generated from stress response and are translationally-stalled,
however, are still able to interact directly with the mitochondria (Onomoto, Jogi et al.
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2012). These stress granules could not be recreated by polyI:C treatment (Onomoto,
Jogi et al. 2012).
SUMOylation, in particular SUMO-2/3 conjugation, has been shown to play an
important role in ischemia (Li, Santockyte et al. 2006, Yang, Sheng et al. 2008, Flotho
and Melchior 2013). Transient ischemia induces a massive increase in protein
SUMOylation within 10 min of onset (Yang, Sheng et al. 2008, Flotho and Melchior
2013). SUMO-2/3 conjugation to p53 and retinoblastoma protein may play a role in
premature senescence and the stress response (Li, Santockyte et al. 2006). Levels of
the Cdk inhibitor, p21, have been shown to be enhanced in cells that over-express
SUMO-2/3 (Li, Santockyte et al. 2006). Although, SUMO-1 conjugation is important, it is
more prominent in a non-stressed cells (Yang, Sheng et al. 2008). Arsenite, a
respiratory poison, induces oxidative stress similar to viral infection and functions to
suppress protein synthesis by phosphorylation of eIF2-alpha, and to activate heat-shock
proteins (Yang, Sheng et al. 2008). Interestingly, western blots of tissues that were
treated with arsenite led to SUMO-1 and SUMO-2/3 profiles with molecular weight
bands of approximately 40, 52, and 70 kDa (Yang, Sheng et al. 2008). These findings
suggest that viral infection or chemical treatments can leads to an increase in
SUMOylation to protect the cell from stress-related effects. The objective of this chapter
is to investigate the interplay between viral infection and the increase in cellular
SUMOylation.
As stated previously, we have determined that SUMOylation of NS1 is required
for viral fitness and that it is the major contributor to the global increase in cellular
SUMOylation. Previously our lab has shown that SUMOylation of NS1 affects NS1’s
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ability to neutralize the host IFN response as well as viral growth (Santos, Pal et al.
2013). Most notably, viruses containing a non-SUMOylatable form of NS1 are able to
cause infection, however, viral titers are 3-logs lower than viruses containing a
SUMOylatable form of NS1 both in interferon-competent and interferon-deficient cell
lines which indicates that the interaction with SUMO is important to the replicative ability
of the virus in tissue culture (Santos, Pal et al. 2013). In this section, we aimed at
investigating whether the ability of NS1 to be SUMOylated has an effect on its ability to
trigger an increase in cellular SUMOylation and whether this increase in cellular
SUMOylation occurs during infection with other viruses.
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3.2 Materials and Methods:
TNT coupled transcription/translation reaction
The TNT coupled transcription/translation reaction was performed according to
manufacturers instructions (Promega). A quick mix containing a rabbit reticulocyte
lysate, TNT reaction buffer, RNA polymerase, amino acid mixture (minus methionine),
an energy source (ATP/GTP), and a ribonuclease inhibitor, is mixed with plasmid,

35S-

Methionine, and MG132 to stabilize the reaction. The reaction was incubated at 30C for
90 minutes and either stored at -80°C or on ice until analyzed by SDS-PAGE or used for
in-vitro SUMOylation reactions. Increasing amount of SUMO1 protein was added to the
samples and incubated at 4°C for 1 hour.

In-vitro SUMOylation reaction
A quick mix containing the SUMO activating enzymes (SAE1/2), GST-Ubc9, SUMO1
protein, 5x SUMOylation reaction buffer, and the TNT sample were mixed and incubated
at 37°C for 90 minutes. Following the incubation, 4x sample buffer and βmercaptoethanol was added up to a final concentration of 10%, and the samples were
boiled in a water bath for 3 minutes.

GST-pulldown
A GST pulldown, using either GST-SUMO1 or GST-SUMO3, was performed in which
glutathione-sepharose beads were used to capture GST fused proteins of interest.
Glutathione-sepharose beads were centrifuged twice at 3,000 rpm for 1 minute, once
with water and once with cold 1x PBS. The beads were then equilibrated with 1x PBS
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supplemented with either GST or GST-NS1 to make a 50% slurry. The reaction was
then incubated at 4°C for 1 hour. The beads were washed with 1x PBS supplemented
with 0.1% Tween 20 in the HulaMixer® Sample Mixer (Life Technologies) for 3 minutes.
Samples were centrifuged at 3,000 rpm for 1 minute and the supernatant removed by
the vacuum system. Samples were mixed with 4x sample buffer and analyzed by
immunoblot.

Transient transfections
HEK293FT cells (Invitrogen Corp.) were seeded at a density of 5 x 105 cells/well into 6
well plates. The following day, cells were transfected by liposome-mediated transfection
using 5 ug of CsCl-purified plasmids and 10 uL of TransIT-LT1 (Mirus Bio LLC) per well,
according to the manufacturer’s recommendations. Cells were incubated at 37ºC in 5%
CO2 for 24 hours. Cell extracts were collected at 1 and 24 hours post-transfection and
analyzed by SDS-PAGE followed by immunoblotting to determine transfection efficiency
of the ASL. Culture supernatant was then discarded and 4x sample buffer and βmercaptoethanol was added up to a final concentration of 10%, and the samples were
boiled in a water bath for 3 minutes.

Immunoblot analyses
Prior to SDS-PAGE analyses, all cell extracts generate were passed several times
through a 29½ gauge needle to break down the genomic DNA released and to decrease
the viscosity of the samples. β-mercaptoethanol was added up to a final concentration
of 10%, and the samples were boiled in a water bath for 3 minutes. The samples were
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resolved by 10% SDS-PAGE gels made in-house and, subsequently, the proteins were
transferred to Immobilon-FL (Millipore Corp., Bedford, MA) for use with IRDyeconjugated secondary antibodies (LI-COR Biosciences Inc., Lincoln, NE) and infrared
fluorescence imaging and analysis by autoradiography and phosphordensitometry.

Autoradiography
The Immobilon-FL membrane was dried and exposed to film (Sigma Aldrich) for 10
minutes, 1 hour, and 18 hours. The image was quantified using Quantity One Software
(Bio-Rad Laboratories, Hercules, CA).

Phosphodensitometry
The Immobilon-FL membrane was dried and exposed to the phosphor screen for 6
hours. The screen was developed 6 hours and quantified using Quantity One Software
(Bio-Rad Laboratories).

Infrared fluorescence imaging
Immobilon-FL membranes (Millipore Corp.) were washed four times in 1x PBS, blocked
with Odyssey Blocking Buffer (LI-COR Biosciences Inc.) for a minimum of 1 hour at
room temperature, and incubated in Odyssey Blocking Buffer at 4°C overnight with the
primary antibody at the indicated dilution. The membranes were then washed four times
with 1x PBS, supplemented with 0.1% polysorbate 20 (Tween 20), and incubated with
Odyssey Blocking Buffer with the appropriate highly cross-absorbed IRDye 800 CWand IRDye 680 LT-conjugated secondary antibodies (LI-COR Biosciences Inc.) at the
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indicated dilution. The membranes were then washed four times with 1x PBS,
supplemented with 0.1% Tween 20 and twice again with 1x PBS and scanned on an
Odyssey CLx infrared imaging system (LI-COR Biosciences Inc.). Quantitative analyses
of the images obtained was performed by using Odyssey Infrared Imaging System
Application software version 3.0.29 (LI-COR Biosciences Inc.). Statistical analyses and
graphics of the data generated were performed by using GraphPad Prism version 5.04
for Windows (GraphPad Software Inc., San Diego, CA).

Isolation and infection of bone marrow derived dendritic cells
Bone marrow derived dendritic cells were isolated from female C57BL/6 mice. On day 8
post-isolation, cells were enriched through magnetic bead sorting for CD11c
(AutoMACS® Pro Separator, Miltenyi Biotec Inc., Auburn, CA). Dendritic cells were
seeded at a density of 3.7 x 106 cells/well in complete medium consisting of 1x Roswell
Park Memorial Institute medium (1x RPMI) supplemented with 10% fetal bovine serum
(Atlanta Biologicals), 1% Penicillin-Streptomycin Solution (Thermo Scientific, Waltham,
MA), and 1% GlutaMAX (Life Technologies Inc., Carlsbad, CA). Cells were maintained
in a 37ºC incubator in 5% CO2. Four hours after plating, the cells were washed twice
with 1 x RPMI, and a viral dilution prepared in 3 mL of 1 x RPMI supplemented with
0.2% BSA was added to the cells and incubated with the cells at 35ºC for 1 hour. The
cells were washed again with 1 x RPMI and the total volume was removed and placed
into a 15 mL conical tube. Tubes were centrifuged at 1000 rpm for 5 minutes to collect
the cells. The supernatant was removed by vacuum and cells were resuspended in 9
mL of 1 x RPMI. Cells were re-plated 3 mL/well and incubated at 35ºC in 5% CO2. At 12
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hours post-infection, the cells were washed with 1 x RPMI and the total volume was
removed and placed into a 15 mL conical tube. Tubes were centrifuged at 1000 rpm for
5 minutes to collect the cells. The supernatant was removed by vacuum and cell
extracts were collected by adding boiling 2x sample buffer (25 mM Tris pH 6.8, 5%
glycerol, 2% SDS, 0.01% bromophenol blue) for SDS-PAGE and immunoblotting
analyses.

Animal infections
All animal experiments were approved by the institutional animal care and use
committee of the University of Maryland-College Park, Department of Veterinary
Medicine. Female, 6-week-old DBA/2J mice (The Jackson Laboratory) were used for
viral pathogenicity experiments. Mice were anesthetized in groups of five by isoflurane
inhalation and infected intranasally with 1x106 PFU of the respective virus in 50 uL of
PBS. To determine differences between clinical signs of disease, a 0-1-2-3 scoring scale
was used, with 0 and 3 representing normal and severe, respectively. Animals were
observed for 2 days for clinical signs of infection. Viral infection was studied in 5 groups
of twenty mice over 6 days. Four mice from each group were sacrificed on hours 0, 6,
12, 24, and 48 after inoculation and lungs and trachea were removed from each mouse
and immediately placed in 10% NBF.

Immunohistochemistry
Approximately 10% of lung tissue from mice at days 4 and 6 post-inoculation were
isolated, washed in sterile PBS, and fixed in 10% NBF. Tissue sample were embedded
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in paraffin, cut into 5-um-thick sections, and mounted onto glass slides. Paraffin was
removed using two washes of xylene followed by ethanol gradient (100%, 95%, and
80%) washes. A 70% ethanol wash was supplemented with 0.25% ammonia and
incubated for 1 hour at room temperature. Slides were incubated in 50% ethanol
followed by two washes in 1x PBS to rehydrate the tissues. Antigens within the tissues
were unmasked by incubating in 1 mM EDTA and heated in a microwave on full power
until the buffer began to boil. The tissues were let cool for 20 minutes and washed three
times with 1x PBS, the last of which was supplemented with sodium borohydride (Sigma
Aldrich) at a concentration of 10 mg/mL, and followed by four washes with 1x PBS.
Tissue sections were drained and a hydrophobic barrier was drawn around each
tissue using an ImmEdge Pen (Vector Laboratories). In order to permeabilize the
tissues, the sections were washed twice with 1x PBS, the second of which was
supplemented with 0.2% Triton X-100 (MP Biomedicals), and followed by three washes
with 1x PBS. Sections were blocked with 1x PBS with 1% goat serum for 1 hour at room
temperature and incubated in 1x PBS with 1% goat serum at 4C overnight with the
primary antibody at the indicated dilution. The sections were then washed four times
with 1x PBS and incubated with 1x PBS with 1% goat serum supplemented with the
appropriate highly cross-absorbed Alexa Fluor 594 and 488 dye conjugated secondary
antibodies (Life Technologies Inc.) at the indicated dilution. Sections were washed three
times in 1x PBS followed by one wash with 1x PBS supplemented with DAPI (Thermo
Scientific) at a final concentration of 0.5 ug/mL. Sections were washed in 1x PBS,
glycerol and glass cover slips were added, and slides were sealed with clear nail polish.
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Statistical analysis and computer software.
All statistical analyses and graphics presented were performed by using GraphPad
Prism version 5.04 for Windows (GraphPad Software Inc.). All figures were created by
using Adobe Photoshop CS5 extended version 12.0.3 X64 (Adobe Systems Inc.).
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3.3 Results:
NS1 proteins from different influenza A viral strains exhibit varying levels of
SUMOylation. Previous studies had characterized the SUMOylation of NS1 from the A/
Puerto Rico/8/1934 [H1N1] strain of influenza, therefore, we sought to determine the
SUMOylation of NS1 proteins from other influenza A viral strains (Table 3.1).
SUMOylated forms of NS1 were detected for all influenza viral proteins (Figure 3.1).
The A/Brevig Mission/1/1918 [H1N1] influenza strain had the appearance of several
new SUMOylated bands in contrast to a single form for all other NS1 proteins.
SUMOylated NS1 was quantified as compared to non-SUMOylated NS1 and it showed
that all influenza viral proteins, except for the A/Brevig Mission/1/1918 [H1N1] NS1, had
less than 4% of SUMOylated NS1, making the non-SUMOylated NS1 the dominant form
(Figure 3.2). Conversely, the A/Brevig Mission/1/1918 [H1N1] influenza strain had more
than 81% of SUMOylated NS1, making the SUMOylated NS1 the dominant form
(Figure 3.2).

SUMOylated NS1 proteins are able to trigger an increase in cellular
SUMOylation. Previous studies using SUMOylatable and non-SUMOylatable NS1
proteins from the A/Puerto Rico/8/1934 [H1N1] influenza A strain showed that an
increase in cellular SUMOylation was only triggered by the SUMOylatable form of NS1.
In order to determine if the SUMOylation of NS1 has an effect on the increase in cellular
SUMOylation, NS1 proteins from different influenza A viral strains were tested. Influenza
NS1 viral proteins that have higher levels of SUMOylation are able to trigger the
increase in cellular SUMOylation more effectively (Figure 3.3). The NS1 proteins from
87

the A/WSN/1933 [H1N1] and A/Brevig Mission/1/1918 [H1N1] were able to trigger the
highest increases in cellular SUMOylation.

Influenza infections ex vivo and in vivo exhibit a global increase in cellular
SUMOylation. An increase in cellular SUMOylation had been observed upon infection
using immortalized cell lines. Therefore, in order to determine whether an increase in
cellular SUMOylation could be triggered in primary cells, bone marrow derived dendritic
cells (BMDCs) were infected with the A/WSN/1933 influenza virus. Both A549 cells and
BMDCs exhibited a global increase in cellular SUMOylation characterized by the
appearance of new SUMOylated bands at 40, 52, and 70 kDa when compared to the
mock-infected samples (Figure 3.4A). It is demonstrated in Figure 3.4B that A549 cells
and BMDCs have increased levels of SUMO1 production upon infection with the A/
WSN/1933 influenza virus. In order to determine whether an increase in cellular
SUMOylation occurred during infections in an animal model, DBA/2J mice were infected
with either the WSN/T7T7[NS1~NS2] or WSN/T7T7[NS1K70AK219A~NS2] influenza
viruses. Lung tissue from mice infected with WSN/T7T7[NS1~NS2] also had the
appearance of new low molecular weight bands, between 25 and 37 kDa, and high
molecular weight bands, between 75 and 100 kDa, as compared to the mock-infected
lung tissue (Figure 3.4C and 3.4D). Lung tissue from mice infected with WSN/
T7T7[NS1K70AK219A~NS2] was tested, however, did not produce new molecular
weight bands characteristic of a global increase in cellular SUMOylation (data not
shown).
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Increases in cellular SUMOylation are observed during influenza A viral
infection in an animal model. To further examine the significance of NS1 SUMOylation
on influenza viral infection, we evaluated changes in cellular SUMOylation from infected
mice at day 6 post-infection Lung tissue harvested from animals infected with the WSN/
T7T7[NS1~NS2] virus showed increases in cellular SUMOylation (Figure 3.5) as
compared to animals infected with the WSN/T7T7[NS1K70AK219A~NS2] virus (Figure
3.6). Similar results were obtained for all animals within each group.
Additionally, in order to determine whether the increase in cellular SUMOylation is
a characteristic shared among different influenza viruses, five groups of four DBA/2J
mice were intranasally infected with 1 x 106 PFU/mL with either A/WSN/33, A/Puerto
Rico/8/1934, A/Hong Kong/1968 (X31), A/Guinea Fowl/Hong Kong/WF10/1999 (WF10)
strains of influenza virus or PBS as a control (Figure 3.7). Mice were euthanized at
hours 0, 6, 12, 24, and 48 post-infection and lungs and trachea were harvested. All
animals infected with the influenza A viruses exhibited increases in cellular
SUMOylation as compared to mock infected tissues (Figure 3.8).

Infections with Vaccinia virus and Lymphocytic choriomeningitis virus
results in an increase in cellular SUMOylation. Previous studies have demonstrated
that influenza A viral infection is able to trigger an increase in cellular SUMOylation,
however, it is unknown whether this increase in cellular SUMOylation occurs upon
infection with other viruses. In order to determine the ability of vaccinia virus and
lymphocytic choriomeningitis virus (referred to as LCMV hereafter) trigger an increase in
cellular SUMOylation, samples infected with either virus were tested. Infection with
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vaccinia virus showed increases in SUMOylation in the high molecular weight region as
compared to non-infected Vero cells (Figure 3.9). Three different strains of LCMV were
used: armstrong (ARM; non-pathogenic strain), armstrong-clone 13 (clone 13; chronic
infection), and WE (pathogenic strain). In addition, a viral vaccine candidate for Lassa
hemorrhagic fever (ML29) was included. The LCMV ARM and clone 13 strain infected
samples showed increases in cellular SUMOylation in the high molecular weight region
at both 48 and 72 hpi (Figure 3.9). In contrast, the pathogenic LCMV WE strain showed
increases in cellular SUMOylation at 48 hpi, however, SUMOylation levels decreased by
72 hpi (Figure 3.9). The ML29 vaccine candidate treated samples showed an increase
in cellular SUMOylation in the high molecular weight region at both 48 and 72 hpi as
compared to the non-infected Vero cells (Figure 3.9).
To determine differences in SUMOylation, we divided the high molecular weight
region into four areas as identified in Figure 3.10A (yellow boxes). The intensity of each
area was quantified to determine the intensity of SUMO as compared to GAPDH, which
was used as a loading control (Figure 3.10B). There was no significant differences
between the samples in rows one, two, or four as compared to the non-infected Vero
cells. However, the quantification of row three showed dramatic increased levels of
SUMOylation in the LCMV ARM and clone 13 infected samples at 72 hpi as compared
to all other samples (Figure 3.10B). In addition, quantification of row three showed
slight increases in SUMOylation in Vero cells and ML29 treated cells and decreases in
SUMOylation in vaccinia virus and LCMV WE infected cells between 48 and 72 hpi
(Figure 3.10B).
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In order to determine whether these changes in cellular SUMOylation were due
to differences in levels in Ubc9, we quantified the intensity of Ubc9 as compared to
GAPDH and found that there were no significant differences between any of the
samples (Figure 3.11). To better resolve the high molecular weight region, we ran a gel
containing a lower percentage of acrylamide which revealed the presence of two new
SUMOylated bands just above 50 kD (Figure 3.12). These two bands appear in all
samples except for the Vero cells.
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Table 3.1. Influenza A viral strains used in studies
Influenza A viral strain

Abbreviation used

Modifications

Figure referenced

A/Puerto Rico/8/1934
[H1N1]

PR8

none

Figure 3.1 - Figure 3.3;
Figure 3.8

A/WSN/1933
[H1N1]

WSN

none

Figure 3.1 - Figure 3.3;
Figure 3.8

A/Memphis/31/1998
[H3N2]

Memphis

none

Figure 3.1 - Figure 3.3

A/Guinea Fowl/Hong Kong/WF10/1999
[H9N2]

WF10

none

Figure 3.3; Figure 3.8

A/Aichi/2/1968
[H3N2]

X31

none

Figure 3.8

A/Zhejiang/DTID-ZJU01/2013
[H7N9]

ZJU

none

Figure 3.1 - Figure 3.3

A/Brevig Mission/1/1918
[H1N1]

BM

none

Figure 3.1 - Figure 3.3

A/Brevig Mission/1/1918
[H1N1]

BM K227S/R

K227S or R
mutation in NS1

Figure 3.1 - Figure 3.3
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Figure 3.1. NS1 proteins from different influenza A viruses exhibit varying
levels of SUMOylation. Mammalian expression plasmids encoding the NS1
proteins from different influenza A viruses were used as the template for a TNT
coupled transcription/translation reaction. An in-vitro SUMOylation reaction was
performed and samples were incubated with (+) or without (-) the SUMO protease,
Ulp1, as indicated. The resulting SUMOylation profile for the NS1 proteins are
shown above. The new SUMOylated NS1 bands are indicated by the arrows.
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Figure 3.2. Quantification of NS1 SUMOylation from different influenza A
viruses. Mammalian expression plasmids encoding the NS1 proteins from different
influenza A viruses were used as the template for a TNT coupled transcription/
translation reaction followed by an in-vitro SUMOylation reaction. Samples were
incubated with (+) or without (-) the SUMO protease, Ulp1, as indicated. The
quantification of the resulting SUMOylation profile for the NS1 proteins is shown
above.
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Figure 3.3. SUMOylated NS1 proteins are able to trigger an increase in cellular
SUMOylation. (A) HEK293FT cells were transfected with the indicated mammalian
expression plasmids encoding the NS1 proteins from A/WSN/33 [H1N1], A/Puerto
Rico/8/1934 [H1N1], A/Memphis/31/1998 [H3N2], A/Guinea Fowl/Hong Kong/
WF10/1999 [H9N2], A/Zhejiang/DTID-ZJU01/2013 [H7N9], and A/Brevig Mission/
1/1918 [H1N1], including a SUMOylatable and non-SUMOylatable form. Samples
were analyzed by SDS-PAGE and immunoblotting using anti-SUMO1 MAb, anti-T7
MAb, anti-Ubc9 MAb, and anti-GAPDH MAb. (B) Quantification of SUMOylated
T7T7NS (between 37 kD and 75 kD) as relative intensity to total T7T7 per lane. (C)
Quantification of SUMO1 (between 37 kD and 75 kD) as relative intensity to total
SUMO1 per lane. MAb: monoclonal antibody.
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Figure 3.4. Influenza infections ex vivo and in vivo exhibit a global increase in
cellular SUMOylation. A549 cells or bone marrow derived dendritic cells (BMDC)
were either mock-infected or infected with A/WSN/33. (A) anti-SUMO1, anti-M1 and
anti-GAPDH MAb. (B) Quantification of SUMO1 and M1 relative intensity as
compared to GAPDH levels in A549 cells or BMDC. DBA/2J mice and A549 cells
were either mock-infected or infected with WSN/T7T7[NS1~NS2]. Lung tissue and
cell extracts, respectively, were analyzed by SDS-PAGE using (C) anti-M1 and antiGAPDH mouse MAb and (D) anti-SUMO1 rabbit MAb. New SUMOylated bands are
indicated by the arrows. MAb: monoclonal antibody.
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Figure 3.5. Animals infected with WSN/T7T7[NS1~NS2] virus exhibit increases
in cellular SUMOylation. 5-6 week old female DBA/2J mice were inoculated with
one of the inocula indicated. At the indicated times post-infection, four animals per
inoculation group were sacrificed and the organs were harvested for
immunohistochemistry analysis. Lung tissue was fixed in formalin, embedded in
paraffin, sectioned, and fixed onto microscope slides. Slides were processed and
stained with DAPI (blue), anti-SUMO1 MAb (red), and anti-NP PAb (green). Images
were taken using confocal microscope. MAb: monoclonal antibody. PAb: polyclonal
antibody.
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Figure 3.6. Animals infected with WSN/T7T7[NS1K70AK219A~NS2] virus do not
exhibit increases in cellular SUMOylation. 5-6 week old female DBA/2J mice were
inoculated with one of the inocula indicated. At the indicated times post-infection, four
animals per inoculation group were sacrificed and the organs were harvested for
immunohistochemistry analysis. Lung tissue was fixed in formalin, embedded in
paraffin, sectioned, and fixed onto microscope slides. Slides were processed and
stained with DAPI (blue), anti-SUMO1 MAb (red), and anti-NP PAb (green). Images
were taken using confocal microscope. MAb: monoclonal antibody. PAb: polyclonal
antibody.
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Figure 3.7. Overall experimental approach. 5-6 week old female DBA/2J mice
were inoculated with one of the inocula indicated. At the indicated times postinfection, four animals per inoculation group were sacrificed and the organs were
harvested for immunohistochemistry analysis.
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Figure 3.8. Animals infected with different influenza A viruses exhibit
increases in cellular SUMOylation albeit to different extents. 5-6 week old
female DBA/2J mice were inoculated with one of the inocula indicated. At the
indicated times post-infection, four animals per inoculation group were sacrificed and
the organs were harvested for immunohistochemistry analysis. Lung tissue was
fixed in formalin, embedded in paraffin, sectioned, and fixed onto microscope slides.
Slides were processed and stained with DAPI (blue), anti-SUMO1 MAb (red), and
anti-NP PAb (green). Images were taken using confocal microscope. MAb:
monoclonal antibody. PAb: polyclonal antibody. Representative images from each
group are presented.
100

Figure 3.9. Infections with Vaccinia virus and LCMV results in an increase in
cellular SUMOylation. VERO cells were infected with Vaccinia virus and LCMV.
Cell extracts were collected at 48 and 72 hours post-infection and analyzed by SDSPAGE (10% acrylamide) and immunoblotting using anti-SUMO1 MAb, anti-Ubc9
MAb, and anti-GAPDH MAb. MAb: monoclonal antibody.
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Figure 3.10. Infection with LCMV results in an increase in cellular SUMOylation
within the 125 to 150 kD range. (A) VERO cells were infected with Vaccinia virus
and LCMV, collected, and analyzed by SDS-PAGE (10% acrylamide) and
immunoblotting using anti-SUMO1 MAb, anti-Ubc9 MAb, and anti-GAPDH MAb. The
high molecular weight region was divided into four regions (yellow boxes). (B)
Quantification of each of the four regions. MAb: monoclonal antibody.
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Figure 3.11. Increases in cellular SUMOylation during LCMV infection are not
due to changes in the level of SUMO conjugating enzyme Ubc9. VERO cells
were infected with Vaccinia virus and LCMV, collected, and analyzed by SDS-PAGE
(10% acrylamide) and immunoblotting using anti-Ubc9 MAb and anti-GAPDH MAb.
The relative intensity of Ubc9 for each sample was quantified as shown in the graph
above (blue bars). MAb: monoclonal antibody.
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Figure 3.12. Infection with Vaccinia virus and LCMV results in the appearance
of two new SUMOylated bands. VERO cells were infected with Vaccinia virus and
LCMV. Cell extracts were collected at 48 and 72 hours post-infection and analyzed
by SDS-PAGE (6% acrylamide) and immunoblotting using anti-SUMO1 MAb. MAb:
monoclonal antibody.
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3.4 Discussion:
Previous studies relating to the role of SUMOylation have characterized the
increase in SUMOylation upon infection with different influenza A viral strains (Pal,
Santos et al. 2011). Despite the ongoing research related to the interplay between the
increase in cellular SUMOylation and viral infection, this is the first and only study that
investigates increases in cellular SUMOylation upon influenza A viral infection in an
animal model. Here, we evaluated the effect of NS1 SUMOylation on the increase in
cellular SUMOylation and studies performed in vitro, tissue culture, and in an animal
model showed that the ability of NS1 to be SUMOylated correlates to its ability to trigger
an increase in cellular SUMOylation. We demonstrate that the global increase in cellular
SUMOylation can be recapitulated in primary immune cells and in infected animal
tissues, indicating that the observed increase is not specific to immortal cell lines.
Furthermore, we show that an increase in cellular SUMOylation is also observed during
viral infection with vaccinia virus and lymphocytic choriomeningitis virus. Overall, our
results indicate that the increase in cellular SUMOylation is not limited to influenza A
viral infection, but may be responsible for acting as a protection mechanism against viral
infection.
Modulation of the cellular SUMOylation system has been shown to be a pathway
that viruses exploit in order to promote viral replication and assembly, or to evade the
host immune response (Flotho and Melchior 2013, Mattoscio, Segre et al. 2013). The
chicken embryo lethal orphan (CELO) adenovirus protein, Gam1, is able to inhibit
SUMOylation by interacting with and promoting the degradation of the E1 activating
enzyme and enhancing viral replication (Boggio, Colombo et al. 2004, Boggio,
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Passafaro et al. 2007). Thus, increasing SUMOylation with the cell would lead to an
inhibition to viral replication. Our laboratory has shown that influenza A viral proteins are
modified by the cellular SUMOylation system and that the influenza viral protein NS1
protein can trigger an increase in cellular SUMOylation (Pal, Rosas et al. 2010, Pal,
Santos et al. 2011, Santos, Pal et al. 2013). We show here that this increase in cellular
SUMOylation is directly related to the ability of NS1 to be SUMOylated.
Vaccinia virus is a member of the poxvirus family and contains a double stranded
DNA genome. Vaccinia virus encodes two viral proteins, E3L and A40R, that are known
targets of the cellular SUMOylation system (Palacios, Perez et al. 2005, Mattoscio,
Segre et al. 2013). The E3L protein has been shown to be essential for virulence
through its ability to bind DNA and double-stranded RNA (Marq, Hausmann et al. 2009)
and transactivation activity of genes involved in apoptosis, the immune response, and
viral pathogenesis (Kwon and Rich 2005, Gonzalez-Santamaria, Campagna et al.
2011). Moreover, the presence of a SIM is required for its stability and its SUMOylation,
although, SUMO modification of the E3L protein negatively regulates its transactivation
activity (Gonzalez-Santamaria, Campagna et al. 2011). The SUMO modification of the
vaccinia virus protein A40R was shown to be required for its specific localization to the
DNA replication sites within the cytoplasm and prevented its self-association (Palacios,
Perez et al. 2005, Mattoscio, Segre et al. 2013). Our studies showed that upon viral
infection with vaccinia virus there is an increase in cellular SUMOylation, possibly
contributing to viral persistence and avoidance of the host immune response.
LCMV is a member of the Arenaviridae family and contains a negative-sense,
single-stranded RNA genome. LCMV replicates in the cytoplasm and that its replication
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can be diminished by increased expression of the PML-NBs that regulate cytokine
signaling within the cell (Djavani, Rodas et al. 2001). Currently, there are no known
LCMV viral proteins that are modified by SUMO. However, the increase in cellular
SUMOylation upon viral infection suggests that LCMV may express at least one viral
protein that is modified by SUMO. Similarly to influenza NS1 protein, the LCMV
nucleoprotein (NP) is able to antagonize the host immune response by binding doublestranded RNA, as well as preventing the nuclear localization of NF-κB (Ortiz-Riano,
Cheng et al. 2012). It is possible that the LCMV NP viral protein may be a target for
SUMO modification.
Altogether, the data suggests that the increase in SUMOylation may be acting as
a protection mechanism against viral infection by activating immune pathways and
preventing apoptosis.
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CHAPTER 4: THE ARTIFICIAL SUMO LIGASE IS EFFECTIVELY EXPRESSED IN
CELLS AND COULD ACT AS A POTENTIAL THERAPEUTIC AGAINST
INFLUENZA A VIRAL INFECTION

4.1 Introduction:
Previous studies have indicated that increasing levels of any members of the
SUMOylation pathway leads to a decrease in viral infection and, conversely, loss of
SUMO modification leads to an increase in viral infection (Ribet and Cossart 2010,
Hwang and Kalejta 2011). Our lab has demonstrated that altering the SUMOylation of
NS1, either by increasing or decreasing, affects its ability to neutralize the host
interferon immune response, however, has no effect on its stability or localization
(Santos, Pal et al. 2013). Increasing the levels of NS1 SUMOylation was done using an
NS11-87-Ubc9 artificial SUMO ligase. This interaction is mediated through NS1’s ability
to form homodimers. Although this data suggests that decreasing the SUMOylation of
NS1 would decrease NS1’s ability to neutralize IFN, based on the data from Chapter 1,
viral infection with influenza viruses containing a non-SUMOylatable NS1 appear to
have enhanced viral fitness and pathogenicity. This suggests that using the NS11-87Ubc9 artificial SUMO ligase to enhance the SUMOylation of NS1 may diminish viral
fitness and pathogenicity.
Many viruses interact with and exploit the SUMOylation system in order to
promote viral replication and evade the host immune response (Mattoscio, Segre et al.
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2013). Most viruses require SUMO modification in order to activate viral proteins for the
recruitment of other viral or cellular factors or for its localization. However, similar to
influenza virus, the Epstein-Barr virus encodes an immediate-early viral protein, Zta,
which has been shown to be a target of SUMO modification. Zta SUMOylation
decreases its transactivation of viral gene expression leading to the establishment of
latentcy as opposed to lytic replication and, ultimately, repressing viral infection
(Wimmer, Schreiner et al. 2012). We believe that use of the NS11-87-Ubc9 artificial
SUMO ligase would allow us to modulate the SUMOylation of NS1 and possibly disrupt
its antagonistic effect on the host immune response.
Furthermore, new technologies, including purified proteins and lentiviruses, are
being utilized for the delivery of therapeutics for cancer therapy and viral infections (Hui,
Yap et al. 2004, McKay, Patel et al. 2006, Patel, Giddings et al. 2013). The use of
protein therapeutics is becoming more advantageous for several reasons: 1) their ability
to perform specific functions that cannot be mimicked by other chemical compounds; 2)
their action is less likely to interfere with biological processes; 3) the body produces
many of the proteins that are being used as therapeutics; 4) they can provide effective
replacement treatment for mutated or deleted genes; 5) the development and approval
of protein therapeutics is faster than other chemical compounds; and 6) proteins are
unique in form and function (Leader, Baca et al. 2008). The use of lentiviral vectors for
delivery of therapeutics have become increasingly more popular due to their preferable
integration pattern into the host genome (Farinelli, Capo et al. 2014). Previous retroviral
vectors were prone to transcriptional activation of surrounding proto-oncogenes through
their integration into enhancer and promoter regions, however, lentiviral vectors have
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overcome this through their integration into actively transcribed genes (Farinelli, Capo et
al. 2014).
Our lab has developed the artificial SUMO ligase, which is a fusion protein
comprised of the first 87 amino acids from NS1 with the E2 conjugating enzyme, Ubc9,
that is able to specifically enhance the SUMOylation of NS1. The objective of this
chapter is to investigate whether the NS11-87-Ubc9 artificial SUMO ligase can be
effectively expressed within cells and assess its effects on influenza viral infection. In
order to investigate this, we used two methods to test the artificial SUMO ligase. First,
the protein was purified through expression in a bacterial cell line followed by GST
pulldowns. The purified protein would be used to transfect cell lines and test for its
expression. In addition, the artificial SUMO ligase was inserted into a lentiviral vector
which was then used to develop cell lines that would stably express the artificial SUMO
ligase. The cell lines would be tested for the expression of the artificial SUMO ligase.
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4.2 Materials and Methods:
Artificial SUMO ligase protein purification
To produce purified protein that can be used as a potential therapeutic, a plasmid was
developed containing the NS1(R38AK41A)1-87-Ubc9 artificial SUMO ligase in a GST
expression vector that allowed for its expression in bacterial cells. The plasmid was
transformed into BL21 competent bacterial cells and protein production was induced
using isopropyl β-D-1-thiogalactopyranoside (IPTG). A GST pulldown was then
performed in which glutathione-sepharose beads were used to capture GST fused
proteins. The RNA binding domain within NS1 has been modified to contain two
mutations within the RNA binding domain which allow the protein to maintain its tubular
structure, however, remain in the soluble fraction during purification (Bornholdt and
Prasad 2008).

Development of stably transduced cell lines
To produce lentiviruses that contain the ASL as a potential therapeutic, a plasmid was
developed containing the NS11-87-Ubc9 artificial SUMO ligase in the pENTR1A
expression vector. Using this plasmid, an in vitro recombination reaction was required to
transfer the ASL cassette into the pLenti vector. Recombinant lentiviruses were
produced by transfection of A549 and MDCK cells with the lentiviral vector system.
A549 and MDCK cells transduced with the lentivirus were maintained in complete media
supplemented with the antibiotic, zeocin.
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GST-pulldown
A GST pulldown, using either GST-SUMO1 or GST-SUMO3, was performed in which
glutathione-sepharose beads were used to capture GST fused proteins of interest.
Glutathione-sepharose beads were centrifuged twice at 3,000 rpm for 1 minute, once
with water and once with cold 1x PBS. The beads were then equilibrated with 1x PBS
supplemented with either GST or GST-NS1 to make a 50% slurry. The reaction was
then incubated at 4°C for 1 hour. The beads were washed with 1x PBS supplemented
with 0.1% Tween 20 in the HulaMixer® Sample Mixer (Life Technologies) for 3 minutes.
Samples were centrifuged at 3,000 rpm for 1 minute and the supernatant removed by
the vacuum system. Samples were mixed with 4x sample buffer and analyzed by
immunoblot.

Transient transfections
HEK293FT cells (Invitrogen Corp.) were seeded at a density of 5 x 105 cells/well into 6
well plates. The following day, cells were transfected by liposome-mediated transfection
using 1 ug of CsCl-purified plasmids and 2 uL of TransIT-LT1 (Mirus Bio LLC, Madison,
WI) per well, according to the manufacturer’s recommendations. Cells were incubated
at 37ºC in 5% CO2 for 24 hours. Cell extracts were collected at 1 and 24 hours posttransfection and analyzed by SDS-PAGE followed by immunoblotting to determine
transfection efficiency of the ASL. Culture supernatant was then discarded and 4x
sample buffer and β-mercaptoethanol was added up to a final concentration of 10%,
and the samples were boiled in a water bath for 3 minutes.
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Transient transfections of purified protein
HEK293FT cells (Invitrogen Corp.), MDCK cell or A549 cells (ATCC) were seeded at a
density of 5 x 105 cells/well into 6 well plates. The following day, cells were transfected
with purified ASL protein at different concentrations using using the Xfect Protein
Transfection Reagent (Clontech Laboratories Inc., Mountain View, CA), according to the
manufacturer’s recommendations. Cells were incubated at 37ºC in 5% CO2. Cell
extracts were collected at 1 and 24 hours post-transfection and analyzed by SDS-PAGE
followed by immunoblotting to determine transfection efficiency of the ASL. Culture
supernatant was then discarded and 4x sample buffer and β-mercaptoethanol was
added up to a final concentration of 10%, and the samples were boiled in a water bath
for 3 minutes.

Immunoblot analyses
Prior to SDS-PAGE analyses, all cell extracts generate were passed several times
through a 29½ gauge needle to break down the genomic DNA released and to decrease
the viscosity of the samples. β-mercaptoethanol was added up to a final concentration
of 10%, and the samples were boiled in a water bath for 3 minutes. The samples were
resolved by 10% SDS-PAGE gels made in-house and, subsequently, the proteins were
transferred to Immobilon-FL (Millipore Corp., Bedford, MA) for use with IRDyeconjugated secondary antibodies (LI-COR Biosciences Inc., Lincoln, NE) and infrared
fluorescence imaging.
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Infrared fluorescence imaging
Immobilon-FL membranes (Millipore Corp.) were washed four times in 1x PBS, blocked
with Odyssey Blocking Buffer (LI-COR Biosciences Inc.) for a minimum of 1 hour at
room temperature, and incubated in Odyssey Blocking Buffer at 4°C overnight with the
primary antibody at the indicated dilution. The membranes were then washed four times
with 1x PBS, supplemented with 0.1% polysorbate 20 (Tween 20), and incubated with
Odyssey Blocking Buffer with the appropriate highly cross-absorbed IRDye 800 CWand IRDye 680 LT-conjugated secondary antibodies (LI-COR Biosciences Inc.) at the
indicated dilution. The membranes were then washed four times with 1x PBS,
supplemented with 0.1% Tween 20 and twice again with 1x PBS and scanned on an
Odyssey CLx infrared imaging system (LI-COR Biosciences Inc.). Quantitative analyses
of the images obtained was performed by using Odyssey Infrared Imaging System
Application software version 3.0.29 (LI-COR Biosciences Inc.). Statistical analyses and
graphics of the data generated were performed by using GraphPad Prism version 5.04
for Windows (GraphPad Software Inc., San Diego, CA).

Immunofluorescence assay of cultured cell lines
HEK293FT or HEK293A cells (Invitrogen Corp.) or MDCK cells (ATCC) were seeded at
a density of 8 x 103 cells/well into 96 well plates. The following day, cells were
transfected with the specified concentrations of purified ASL protein using the Xfect
Protein Transfection Reagent (Clontech Laboratories Inc.), according to the
manufacturer’s recommendations. Cells were incubated at 37ºC in 5% CO2 for 24
hours. The supernatant was then discarded and the cells were fixed with 4%
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paraformaldehyde for 15 minutes at room temperature. The fixative was aspirated and
the cells were rinsed three times with 1x PBS, blocked with 1x PBS supplemented with
1% goat serum for a minimum of 1 hour at room temperature, and incubated in 1x PBS
supplemented with 1% goat serum at 4°C overnight with the primary antibody at the
indicated dilution. The cells were then washed three times with 1x PBS, and incubated
with 1x PBS supplemented with 1% goat serum with the appropriate highly crossabsorbed AlexaFluor 594 and AlexaFluor 488 fluorophore-conjugated secondary
antibodies (LI-COR Biosciences Inc.) at the indicated dilution. Sections were washed
three times in 1x PBS followed by one wash with 1x PBS supplemented with DAPI
(Thermo Scientific) at a final concentration of 0.5 ug/mL. After 10 minutes, the cells
were washed two additional times and analyzed using the confocal microscope.

Viral Infection
MDCK, MDCK-ASL, or HEK293A cells were plated into 96-well or 12 well plates at a
density of 2.0 x 105 or 1.6 x 104 cells/well, respectively, in either 1x DMEM
supplemented with 10% FBS (for MDCK and MDCK-ASL) or 10% Fetal Plex (for
HEK293FT). The next day the cells were washed once with 1x DMEM, and a virus
dilution prepared in 1x DMEM supplemented with 0.2% BSA was added to the cells and
incubated with the cells at 37°C in 5% CO2 for 24 hours (96-well) or for 1 hour (12-well).
For the 96-well plate: 24 hours post-infection the plate was processed for analysis by
immunofluorescence assay. For the 12-well plate: the supernatant was then removed
and replaced with 1x DMEM supplemented with 1% TPCK-treated trypsin. A portion of
the viral supernatants were collected at this time (0 hours post-infection), labeled, and
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stored at -80°C. The plates were incubated at 37°C in 5% CO2 for an additional 24
hours. Viral supernatants were collected at 24 hours post-infection, labeled, and stored
at -80°C. Total cell extracts were collected in 4x sample buffer for analysis by SDSPAGE.

TCID50 to determine viral titers
MDCK cells were plated into 96-well plates at a density of 1.6 x 105 cells/well in 1x
DMEM supplemented with 10% FBS and incubated at 37°C in 5% CO2 until the cells
formed a confluent monolayer. The cells were then washed once with 1x DMEM, and a
virus dilution prepared in 1ml of 1x DMEM supplemented with 0.2% BSA was added to
the cells and incubated with the cells at 37°C in 5% CO2 for 3 days until cytopathic
effects (CPE) were observed. 50 µL of the supernantants from TCID50 plates were
transferred to a 96-well V-bottom plate (Corning Incorporated Life Sciences). 50 µL of
0.5% turkey red blood cells (Lampire Biological Laboratories, Pipersville, PA)
suspended in 1x PBS, were added to the V-bottom plate and gently tapped to mix.
Plates were incubated at room temperature for 45 minutes. Plates were scored and viral
titers were determined using the Reed-Muench method.

Statistical analysis and computer software.
All statistical analyses and graphics presented were performed by using GraphPad
Prism version 5.04 for Windows (GraphPad Software Inc.). All figures were created by
using Adobe Photoshop CS5 extended version 12.0.3 X64 (Adobe Systems Inc.).
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4.3 Results:
Transfection of the purified protein form of the artificial SUMO ligase can
be achieved in multiple cell lines. Previous studies had shown that modulation of NS1
SUMOylation affects its ability to neutralize the host IFN response (Santos, Pal et al.
2013). We have developed an novel tool, the artificial SUMO ligase (ASL), in order to
specifically enhance the SUMOylation of NS1. To determine whether we can deliver the
ASL purified protein into the cell, we transfected different cell lines with the protein and
then analyzed for its presence at different times post-transfection. We were able to
detect the ASL in transfected HEK293FT, MDCK, and A549 cells (Figure 4.1).

The purified protein form of the artificial SUMO ligase is located in the
cytoplasm of transfected cells. In order to determine whether the protein was being
delivered into the cells and not simply remaining stuck at the plasma membrane,
immunofluorescence assays were performed. HEK293FT cells were transfected with
different concentrations of ASL protein and its localization was determined by confocal
microscope. Cells transfected with 0.1 or 0.4 µg/µL of the ASL protein showed mostly
cytoplasmic localization (Figure 4.2). Conversely, cells transfected with 1.0 or 4.0 µg/
µL of the ASL protein showed mostly extracellular localization (Figure 4.2).

Transfection with purified GST or GST-ASL results in decreased viral
replication. In order to determine the effect of the transfected purified ASL during
influenza viral infection, MDCK cells were either not transfected or transfected with 0.4
µg/µL either purified GST-ASL, or GST as a control, and subsequently infected with A/
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Puerto Rico/8/1934 [H1N1] influenza virus at an MOI of 0.5. Total cell extracts were
analyzed by immunoblot and viral supernatants were quantified by TCID50. Although the
exogenous GST or GST-ASL could not be detected by immunoblot (Figure 4.3A), cells
transfected either with GST or GST-ASL resulted in substantially lower viral titers as
compared to non-transfected cells (Figure 4.3B).

The artificial SUMO ligase is expressed at low levels in transduced cells. As
an alternative delivery method of the ASL protein, a lentivirus was developed and used
to transduce two different cell lines, MDCK and A549. Stably transduced cell lines were
selected for zeocin antibiotic resistance and maintained in complete medium
supplemented with zeocin. To determine whether the ASL is expressed in transduced
cells, cells from each of the cell lines were collected and analyzed for the presence of
the ASL. Both MDCK and A549 cell lines expressed the ASL (Figure 4.4A). The
expression of the ASL protein was quantified as compared to the intensity of GAPDH
and showed that the intensity of the ASL in MDCK cells was found to be approximately
1.4% and 1.8% of the intensity measured for GAPDH in MDCK and A549 cells,
respectively (Figure 4.4B).

The artificial SUMO ligase is expressed within the cytoplasm of transfected
cells. In order to determine the location of transduced ASL, HEK293A cells were
transfected with a plasmid expressing the ASL and its localization was determined by
confocal microscope. Cells transfected with the ASL protein showed both nuclear and
cytoplasmic localization (Figure 4.5).
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Plasmid transfection with HA-Ubc9 or artificial SUMO ligase (NS1(1-87)-Ubc9)
results in decreased viral infection. To determine how expression of the artificial
SUMO ligase affects viral infection, HEK293A cells were either not transfected or
transfected with either the plasmid encoding the ASL, or NS1(1-87), HA-Ubc9 or an empty
plasmid as controls, and subsequently infected with A/Puerto Rico/8/1934 [H1N1]
influenza virus at an MOI of 5. Although infected cells were observed in every sample
(Figure 4.6), there were slightly fewer infected cells in samples transfected with the
ASL.

Expression of the artificial SUMO ligase increases upon viral infection and
results in higher viral titers. In order to determine how the expression of the ASL
affects influenza viral infection, we infected either MDCK cells or the stably transduced
MDCK-ASL cells with A/Puerto Rico/8/1934 [H1N1] influenza virus at an MOI of 0.5.
Total cell extracts were collected and analyzed by SDS-PAGE. Immunoblot analysis
showed that the ASL protein and the influenza late viral protein, M1, was detectable at
24 hours post-infection in MDCK-ASL, however, was not detectable in infected MDCK
cells (Figure 4.7A). The expression of the ASL protein was quantified as compared to
the intensity of GAPDH and showed that the intensity of the ASL in MDCK-ASL cells
was found to be approximately 21% of the intensity measured for GAPDH in MDCKASL cells (Figure 4.7B, left panel). The expression of the M1 viral protein was
quantified as compared to the intensity of GAPDH and showed that the intensity was
found to be approximately 0% and 2% of the intensity measured for GAPDH in MDCK
and MDCK-ASL cells, respectively (Figure 4.7B, right panel). Viral supernatants were
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quantified by TCID50. Stably transduced MDCK-ASL cells had increased levels of viral
titers as compared to non-transduced MDCK cells at both 0 and 24 hours post-infection
(Figure 4.7C).
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Figure 4.1. Transfection of the purified protein form of the artificial SUMO
ligase can be achieved in multiple cell lines. HEK293FT, MDCK, and A549 cells
were transfected with the plasmid encoding the ASL or with purified ASL protein.
Samples were analyzed by SDS-PAGE and immunoblotting using anti-Ubc9 MAb.
MAb: monoclonal antibody.
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Figure 4.2. The purified protein form of the artificial SUMO ligase is located in
the cytoplasm of transfected cells. HEK293FT cells were harvested for
immunofluorescence analysis. Cells were fixed in paraformaldehyde and were
processed and stained with DAPI (blue), anti-Ubc9 MAb (red), and anti-GST MAb
(green). Images were taken using confocal microscope. MAb: monoclonal antibody.
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B.

Figure 4.3. Transfection with purified GST or GST-ASL results in decreased
viral replication. MDCK cells were transfected with either purified GST or GSTASL and infected with A/Puerto Rico/8/1934. (A) Samples were analyzed by SDSPAGE and immunoblotting using anti-M1, anti-GST MAb, anti-GAPDH MAb, and
anti-Ubc9. (B) Quantification of viral titers was performed by TCID50. Error bars
indicate standard deviation. ***, P<0.0001. MAb: monoclonal antibody.
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Figure 4.4. The artificial SUMO ligase is expressed at low levels in transduced,
non-infected cells. MDCK and A549 cells were transduced using a lentiviral vector
containing the ASL. (A) Samples were analyzed by SDS-PAGE and immunoblotting
using anti-Ubc9 MAb and anti-GAPDH MAb. (B) Quantification of the transduced
ASL as relative intensity to GAPDH. MAb: monoclonal antibody.
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Figure 4.5. The artificial SUMO ligase is expressed within the nucleus and
cytoplasm of transfected cells. HEK293A cells were not transfected or transfected
with a plasmid that encodes the ASL. Samples were analyzed by
immunofluorescence assay using anti-Ubc9. MAb: monoclonal antibody.
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Figure 4.6. Plasmid transfection with HA-Ubc9 or artificial SUMO ligase
(NS1(1-87)-Ubc9) results in decreased viral infection. HEK293A cells were not
transfected or transfected with either a plasmid that encodes an empty vector,
NS1(1-87), HA-Ubc9, or the ASL. 24 hours post-transfection samples were infected
with A/Puerto Rico/8/1934 influenza virus. 24 hours post-infection, samples were
analyzed by immunofluorescence assay using anti-M1 and GFP. MAb: monoclonal
antibody.
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C.

Figure 4.7. Expression of the artificial SUMO ligase increases upon viral
infection and results in higher viral titers. MDCK and MDCK-ASL cells were
infected with A/Puerto Rico/8/1934. (A) Samples were analyzed by SDS-PAGE and
immunoblotting using anti-M1 MAb, anti-GAPDH MAb, and anti-Ubc9. (B)
Quantification of the transduced ASL (left panel) and M1 (right panel) as relative
intensity to GAPDH. (C) Quantification of viral titers was performed by TCID50. Error
bars indicate standard deviation. *, P<0.05. MAb: monoclonal antibody.
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4.4 Discussion:
Previous studies relating to the use of the NS11-87-Ubc9 artificial SUMO ligase
showed that increasing NS1 SUMOylation decreased its ability to neutralize the host
IFN response (Santos, Pal et al. 2013). Despite the ongoing research related to the
effect of NS1 SUMOylation on viral infection, this is the first and only study that
investigates whether the NS11-87-Ubc9 artificial SUMO ligase can be effectively
expressed within cells and be considered as a novel treatment against influenza viral
infection. We demonstrate that the NS11-87-Ubc9 artificial SUMO ligase in the purified
protein form can be effectively transfected into different cell lines. Furthermore, we show
that the protein form of the NS11-87-Ubc9 artificial SUMO ligase locates to the cytoplasm
of transfected cells which could potentially interact with the cytoplasmic fraction of NS1.
In addition, we show that the NS11-87-Ubc9 artificial SUMO ligase can be constitutively
expressed in stably transduced cells produced by lentiviral transduction, albeit at
substantially lower levels, and that its expression is both nuclear and cytoplasmic. The
transduced ASL could potentially interact with both the nuclear and cytoplasmic
fractions of NS1 regulating its function. Overall, our results indicate that the two
methods used to deliver the NS11-87-Ubc9 artificial SUMO ligase are effective.
Infections performed in purified protein-transfected cells resulted in lower viral
titers as compared to non-transfected cells. Although the GST and GST-ASL transfected
cells had very similar titers, the data suggests that the transfection itself may be
inhibiting viral infection. This would be a reasonable explanation considering previous
studies demonstrating that transfection reagents can induce IFN and IFN-stimulated
genes (Li, Boyanapalli et al. 1998). In addition, infections performed in plasmid129

transfected cells resulted in a markedly reduced number of infected cells in both HAUbc9 and ASL transfected samples as compared to NS1(1-87), empty, or non-transfected
samples. The data obtained from transfecting HA-Ubc9 is in agreement with previous
experiments performed in our lab demonstrating that over-expression of Ubc9 prevents
viral infection (Melendez et al., manuscript in preparation). This data suggests that
expression of the ASL is effective at limiting viral infection.
In contrast, infections performed in the stably transduced MDCK-ASL cell line
resulted in higher expression of the ASL protein and increased viral titers as compared
to MDCK infected cells. Previously, we observed low levels of ASL protein in noninfected samples, however, the expression of the ASL protein was induced during viral
infection. In terms of viral titers, the difference in viral titers at 24 hours post-infection
may be due to the abundance of virus at 0 hours post-infection. If this difference is
accounted for, the viral titer of the MDCK-ASL cells would be lower than that of the
MDCK cells, further supporting the ASL at limiting viral infection.
Most viral proteins have been shown to be activated upon SUMO modification
and may regulate their activity during viral infection. The E1B-55K protein encoded by
adenoviruses is a target for SUMO modification and acts as a SUMO-1 specific E3
ligase to promote viral replication (Mattoscio, Segre et al. 2013). Similarly, the K-bZip
protein encoded by Kaposi’s sarcoma associated herpesvirus is a target for
SUMOylation and acts as a SUMO-2/3 specific E3 ligase in order to regulate the cell
cycle and apoptosis (Mattoscio, Segre et al. 2013). In addition, viral proteins encoded
by vaccinia virus, bovine and human papillomavirus, and cytomegalovirus that regulate
viral replication or viral capsid assembly and are all targets for the SUMOylation system
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appear to require this modification to exert their function (Boggio and Chiocca 2006,
Mattoscio, Segre et al. 2013). Although the influenza NS1 protein does not require
SUMO modification to antagonize the host immune response, previous studies have
demonstrated that altering its levels of SUMOylation have negative effects on its
function and have provided some insight on how influenza viruses are able to interact
with the SUMOylation system (Pal, Santos et al. 2011). Therefore, finding viral targets
that are not only SUMO targets, but also play a role in the manipulation of the cellular
SUMOylation system could lead to potential targets for a new generation of
therapeutics.
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CHAPTER 5: FINAL CONCLUSIONS AND FUTURE DIRECTIONS

5.1 Overview and Final Conclusions:
The focus of the first part of this dissertation was to investigate the relevance of
NS1 SUMOylation during influenza A viral infection. Our laboratory has shown that
influenza A viral proteins are modified by the cellular SUMOylation system and that the
influenza viral protein NS1 protein can trigger an increase in cellular SUMOylation (Pal,
Rosas et al. 2010, Pal, Santos et al. 2011, Santos, Pal et al. 2013). Furthermore, we
identified K70 and K219 as the two main SUMOylation sites within NS1 (Santos, Pal et
al. 2013). Here, we evaluated the effects of mutations affecting NS1 SUMOylation in
both a tissue culture and a mouse model of influenza infection. We found that compared
to a virus carrying a SUMOylatable NS1 protein, infection with a virus containing a nonSUMOylatable NS1 resulted in the increase of clinical symptoms, morbidity, and
mortality. Furthermore, we showed that inhibition of NS1 SUMOylation enabled viral
replication in a broad range of organs as well as increase the pathology of influenza
viral infection. Previous studies had suggested that NS1 SUMOylation regulated protein
stability (Xu, Klenk et al. 2011), however, the enhanced infection with viruses containing
a non-SUMOylatable NS1 favor a model in which NS1 SUMOylation regulates NS1’s
ability to interact with other cellular factors. Overall, our results indicated that a virus
carrying a non-SUMOylatable NS1 exhibits increased viral pathogenicity as compared
to an otherwise identical virus carrying a SUMOylatable NS1.
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In the second part of this dissertation, we evaluated the effect of NS1
SUMOylation and its ability to trigger the increase in cellular SUMOylation. Our studies
performed in vitro, tissue culture, and in an animal model showed that the ability of NS1
to be SUMOylated correlates to its ability to trigger an increase in cellular SUMOylation.
We demonstrated that the global increase in cellular SUMOylation could be
recapitulated in primary immune cells and in infected animal tissues. These results
indicate that the observed increase is not specific to immortal cell lines and may be
relevant for influenza viral infections in animals. Moreover, we show that this increase in
cellular SUMOylation is directly related to the ability of NS1 to be SUMOylated.
Furthermore, we also observed an increase in cellular SUMOylation during viral
infection with vaccinia virus and lymphocytic choriomeningitis virus. Overall, our results
indicate that the increase in cellular SUMOylation is not limited to influenza A viral
infection, but may be relevant for other viral infections. It is possible that the increase in
cellular SUMOylation is responsible for acting as a protection mechanism against viral
infection.
It is known that some viruses exploit the cellular SUMOylation system in order to
promote viral replication and assembly, or to evade the host immune response (Flotho
and Melchior 2013, Mattoscio, Segre et al. 2013). Thus, altering the activity of the cellular

SUMOylation system may inhibit viral replication. Our lab previously demonstrated that
altering the SUMOylation of NS1, either by increasing it or decreasing it, affects its
ability to neutralize the host interferon immune response, but exerts no effect on its
stability or localization (Santos, Pal et al. 2013). However, infections with viruses
containing NS1‘s that were non-SUMOylatable in animals enhanced viral fitness and
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pathogenicity. Therefore, our laboratory has developed an artificial SUMO ligase that
has been shown to specifically enhance NS1 SUMOylation during influenza viral
infection (Santos, Pal et al. 2013). The function of the NS11-87-Ubc9 artificial SUMO ligase
is mediated through NS1’s ability to form homodimers. Our data suggests that using the
NS11-87-Ubc9 artificial SUMO ligase to enhance the SUMOylation of NS1 may diminish
viral fitness and pathogenicity.
Therefore, in the third part of this dissertation, we investigated whether the
NS11-87-Ubc9 artificial SUMO ligase could be effectively expressed within cells and be
considered as a novel treatment against influenza viral infection. We demonstrated that
the NS11-87-Ubc9 artificial SUMO ligase in the purified protein form can be effectively
transfected into different cell lines and that it locates to the cytoplasm of transfected
cells. In addition, we show that the NS11-87-Ubc9 artificial SUMO ligase can be
expressed in lentivirus transduced cells. Our results indicate that the two methods used
to deliver the NS11-87-Ubc9 artificial SUMO ligase are effective.
Overall, our results from this dissertation suggest that NS1 SUMOylation may act
as a good predictor of viral pathogenicity and that the increase in cellular SUMOylation
is triggered to enhance the SUMOylation of cellular factors in order to promote cell
proliferation and prevent apoptosis. We believe that use of the NS11-87-Ubc9 artificial
SUMO ligase will be an effective treatment against influenza A viral infection by
decreasing NS1’s ability to antagonize the host immune response.
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5.2 Future directions:
In this study, we have characterized the relevance of NS1 SUMOylation on viral
infection. However, we have failed to test the relevance of the other influenza viral
proteins that are modified by SUMO during influenza viral infection. Further studies
would be required to determine the relevance of SUMOylation for the other influenza
viral proteins. Furthermore, it would be important to determine the relevance of NS1
SUMOylation in different strains of influenza (i.e. high pathogenic versus low
pathogenic).
In studies looking at the increase in cellular SUMOylation, we found that the
SUMOylatable NS1 is able to trigger the increase in cellular SUMOylation whereas the
non-SUMOylatable NS1 is not. However, it is unknown why this difference exists. It is
possible that the non-SUMOylatable NS1 is able to exert its functions through its two
putative SIMs. The two SIMs may allow NS1 to function either through a new set of
protein-protein interactions or through the activation and regulation of its transcriptional
initiation activity allowing for rapid replication in an attempt to overcome the host
immune response. SIM deficient viruses (Table 5.1) would provide further insight on the
relevance of NS1 SUMOylation during viral infection.
In addition, we observed increases in cellular SUMOylation upon infection with
vaccinia virus and LCMV. If the increase in cellular SUMOylation is dependent upon the
SUMOylation of one of its viral proteins, it would further support the relevance of
SUMOylation in viral infections. In addition, it may provide evidence of potential targets
for drug development.
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The results here provide initial insights into the use of the NS11-87-Ubc9 artificial
SUMO ligase as a potential therapeutic against influenza viral infection. In order to
validate it as a potential therapeutic against influenza A virus, further studies
investigating its ability to decrease viral infection in both tissue culture and an animal
model need to be performed.
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Table 5.1. Properties of plasmids developed and their modifications
Plasmids

T7T7 tag

Other modifications

1. pcDNA3/Pol2/T7T7[NS1L144AI145A]

Yes

mutations in SIM1

2. pcDNA3/Pol2/T7T7[NS1K70L144AI145AK219A]

Yes

mutations in SIM1;
SUMOylation deficient

3. pcDNA3/Pol2/T7T7[NS1V178AV180A]

Yes

mutations in SIM2

4. pcDNA3/Pol2/T7T7[NS1K70AV178AV180AK219A]

Yes

mutations in SIM2;
SUMOylation deficient

5. pcDNA3/Pol2/T7T7[NS1L144AI145AV178AV180A]

Yes

mutations in SIM1/SIM2

6. pcDNA3/Pol2/T7T7[NS1K70AL144AI145AV178AV180AK219A]

Yes

mutations in SIM1/SIM2;
SUMOylation deficient
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APPENDIX A
List of Abbreviations

A549

adenocarcinomic human alveolar basal epithelial cells

ADP

adenosine diphosphate

Akt

protein kinase B; serine/threonine specific protein kinase

ASL

artificial SUMO ligase

ATF

activating transcription factor

ATP

adenosine triphosphate

BM

A/Brevig Mission/1/1918 [H1N1] influenza virus

BMDCs

bone marrow derived dendritic cells

BSA

bovine serum albumin

C57BL/6

mouse inbred strain

CELO

chick embryo lethal orphan

CK2

casein kinase II

CPE

cytopathic effects

CPSF30

cleavage and polyadenylation specificity factor 30 kDa subunit

CRD1

cysteine rich domain 1

Crk

adapter molecule; proto-oncogene

CrkL

adapter molecule; proto-oncogene

cRNA

complementary ribonucleic acid

DAPI

4’,6-diamidino-2-phenylindole

DBA/2J

mouse inbred strain

DMEM

Dulbecco’s modified eagle medium

DNA

deoxyribonucleic acid

dpi

days post-infection
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dsDNA

double stranded deoxyribonucleic acid

dsRNA

double stranded ribonucleic acid

EBV

Epstein-Barr virus

ED

effector domain

EDTA

ethylenediaminetetraacetic acid

EF-2

elongation factor 2

eIF2α

eukaryotic initiation factor 2 alpha

env

envelope protein

FBS

fetal bovine serum

FDA

Food and Drug Administration

GAPDH

glyceraldehyde 3-phosphate dehydrogenase

GATA-1

globin transcription factor 1

GST

glutathione S-transferase

GTP

guanosine-5’-triphosphate

GTPase

hydrolase enzymes that act on guanosine triphosphate

H&E

hematoxylin and eosin

HA

hemagglutinin

HCMV

human cytomegalovirus

HDACs

histone deacetylases

HEK

human embryonic kidney cells

HHV6

human herpesvirus 6

HIV-1

human immunodeficiency virus 1

hpi

hours post-infection

HSF1

heat shock transcription factor 1

HSF46

heat shock transcription factor 46

HSV

herpes simplex virus

HTLV-1

human T-lymphotropic virus 1
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HTNV

Hantaan river virus

ICP0

infected cell polypeptide 0

IE1

immediate early protein 1

IE2

immediate early protein 2

IFN

interferon

IL

interleukin

IPTG

isopropyl β-D-1-thiogalactopyranoside

IRF1

interferon regulatory factor 1

IRF3

interferon regulatory factor 3

IRF7

interferon regulatory factor 7

JAK

janus kinase

K-bZIP

Kaposi’s sarcoma-associated herpesvirus-basic region-leucine
zipper

kDa

kilodalton

KSHV

Kaposi’s sarcoma-associated herpesvirus

LCMV

lymphocytic choriomeningitis virus

LGP2

laboratory of genetics and physiology 2

LLO

listeriolysin O

M1

matrix protein 1

M2

matrix protein 2

MAb

monoclonal antibody

MAPK

mitogen-activated protein kinase

MDA5

melanoma differentiation-associated protein 5

MDCK

Madin-Darby canine kidney cells

Memphis

A/Memphis/31/1998 [H3N2] influenza virus

mRNA

messanger ribonucleic acid

MuLV

Moloney murine leukemia virus
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NA

neuraminidase

NBF

neutral phosphate buffered formalin

NF-κB

nuclear factor kappa-light-chain-enhancer of activated B cells

NP

nucleoprotein

NS1

non-structural protein 1

NS2/NEP

non-structural protein 2/nuclear export protein

NXF2

nuclear ribonucleic acid export factor 2

OAS

2’,5’ oligo A synthetase

ORF

open reading frame

PA

polymerase acidic

PAb

polyclonal antibody

PABPI

poly(A) binding protein I

PABPII

poly(A) binding protein II

PAMPs

pathogen-associated molecular patterns

PB1

polymerase basic protein 1

PB2

polymerase basic protein 2

PBS

phosphate buffer solution

PCR

polymerase chain reaction

PDZ

post-synaptic density protein (PSD95); Drosophila disc large
tumor suppressor (Dlg-1); zonula occludens-1 protein (zo-1)

PFO

perfringolysin O

PFU

plaque forming units

PI3K

phosphatidylinositol 3-kinase

PIAS

protein inhibitor of activated signal transducer and activator of
transcription

PKR

protein kinase R

PLO

pyolysin O
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PML NBs

promyelocytic leukemia nuclear bodies

PR8

A/Puerto Rico/8/1934 [H1N1] influenza virus

PRRs

pattern recognition receptors

PV

papillomavirus

RanGAP

Ran GTPase activating protein

RBD

ribonucleic acid binding domain

RdRp

RNA dependent RNA polymerase

rER

rough endoplasmic reticulum

RhoA

Ras homolog gene family, member A

RIG-I

retinoic acid-inducible gene I

RLRs

RIG-I like receptors

RNA

ribonucleic acid

RPMI

Roswell Park Memorial Institute medium

RSAR

RNA-silencing antiviral response

RT-PCR

reverse transcription-polymerase chain reaction

SA

splicing acceptor

SAE1/2

SUMO activating enzyme subunit 1/ subunit 2

SARS

severe acute respiratory syndrome

SARS CoV

severe acute respiratory syndrome coronoavirus

SATB2

special AT-rich sequence-binding protein 2

SD

splicing donor

SDS-PAGE

sodium dodecyl sulfate polyacrylamide gel electrophoresis

SENP

sentrin-specific protease

SEOV

Seoul virus

SH2

Src homology 2 domain

SH3

Src homology 3 domain

SIM

SUMO interacting motif
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STAT

signal transducer and activator of transcription

SUMO

small ubiquitin-like modifier

TCID50

tissue culture infectious dose

TLRs

toll like receptors

TNFα

tumor necrosis factor alpha

TPCK

L-1-tosylamide-2-phenylethyl chloromethyl ketone

TRAIL

tumor necrosis factor-related apoptosis-inducing ligand

TRIM25

tripartite motif containing 25

TULV

Tula virus

Tween 20

polysorbate 20

UIM

ubiquitin interacting motif

UTR

untranslated region

VERO

African green monkey kidney cell line

vRNA

viral ribonucleic acid

vRNPs

viral ribonuceloproteins

VV

vaccinia virus

WF10

A/Guinea Fowl/Hong Kong/WF10/1999 [H9N2] influenza virus

WSN

A/Wilson Smith Neurotropic/1933 [H1N1] influenza virus

X31

A/Aichi/2/1968 [H3N2] influenza virus

ZJU

A/Zhejiang/DTID/ZJU01/2013 [H7N9] influenza virus
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List of Developed Constructs

pPol1/WSN/T7T7NS-PR8
pPol1/WSN/T7T7NS(K70A)-PR8
pPol1/WSN/T7T7NS(K219A)-PR8
pPol1/WSN/T7T7NS(K70AK219A)-PR8
pcDNA3/Pol2/NS1(R38AK41A)-Ubc9
pcDNA3/Pol2/NS1(1-87)-Ubc9
pcDNA3Pol1Pol2/NS1(1-87)R38AK41A-Ubc9
pcDNA3PolIPolIIT7T7NS1K219E
pcDNA3/Pol2/NS1(1-87)(R38AK41A)-Ubc9
pTE1[Adaptor]S1
pTE1[NS1(1-87)-Ubc9]S1
pcDNA3/Pol1/Pol2/T7T7NS1(R38AK41A)
pcDNA3/Pol1/Pol2/T7T7NS1(R38AK41AK70AK219A)
pcDNA3/Pol1/Pol2/NS1(1-87)(R38AK41A)
pPol1/WSN/PR8[T7T7NS(R38AK41A)]
pPol1/WSN/PR8[T7T7NS(R38AK41A)]-SplAccepMut
pcDNA3/Pol2/T7T7NS1 (K70AK219A)
pcDNA3/Pol2/T7T7NS2
pcDNA3/Pol2/NS1(1-87)-Ubc9
pcDNA3/Pol2/NS1(1-87)
pcDNA3/Pol2/NS1(1-87) (R38AK41A)
pcDNA3/Pol2/T7T7NS1 (R38AK41A)
pcDNA3/Pol2/T7T7NS1 (R38AK41AK70AK219A)
pENTR1a/[PR8 NS]
pENTR1a/[PR8 NS1(K70AK219A)~NS2]
pcDNA5/FRT/TO/Alpha-synuclein(1-57)-HA-Ubc9
pcDNA5/FRT/TO/Alpha-synuclein(58-107)-HA-Ubc9
pcDNA5/FRT/TO/Alpha-synuclein(108-140)-HA-Ubc9
pcDNA3/Pol2/T7T7NS1
pPol1/WSN/NS-SplAccptMut
pPol1/WSN/T7T7NS(K219E)-PR8
pPol1/WSN/T7T7NS1(K20AK219E)-PR8
pPol1/WSN/T7T7NS1(R38AK41A)~EGFP
pcDNA3/Pol1/Pol2/T7T7NS1(K219R)
pcDNA3/Pol1/Pol2/BPV-E2(285-365)~Ubc9
pcDNA5/FRT/TO/HA-Ubc9-HPV-E2(220-365)
pcDNA3/Pol2/GST-T7NS1
pcDNA3/Pol1/Pol2/T7NS-WSN

pcDNA3/Pol1/Pol2/T7NS-Brevig Mission
pcDNA3/Pol1/Pol2/T7NS-Memphis
pcDNA3/Pol1/Pol2/T7NS-Memphis
pcDNA3/Pol1/Pol2/T7NS(K227S)-Brevig Mission
pcDNA3/Pol1/Pol2/T7NS-ZJU
pGEX4T1[NS1(R38AK41A)][Ubc9]
pGEX4T1[NS1(R38AK41AK70AK219A)]
pPol1/WSN/T7NS-Brevig Mission
pPol1/WSN/T7NS(K227S)-Brevig Mission
pPol1/WSN/T7NS-ZJU
pPol1/WSN/T7NS-Memphis
pcDNA3/Pol2/T7NS-WSN
pcDNA3/Pol2/T7NS-Memphis
pcDNA3/Pol2/T7NS-Brevig Mission
pcDNA3/Pol2/T7NS(K227S)-Brevig Mission
pcDNA3/Pol2/T7NS-ZJU

pcDNA3/Pol2/T7T7NS/WSN1
pPol1/WSN/T7T7NS-Brevig Mission
pPol1/WSN/T7T7NS(K227S)-Brevig Mission
pPol1/WSN/T7T7NS-ZJU
pPol1/WSN/T7T7NS-Memphis
pPol1/WSN/T7T7NS-WSN
pPol1/WSN/T7T7NS-WF10
pPol1/WSN/T7NS-WF10
pcDNA3/Pol2/T7NS-WF10
pcDNA3/Pol2/T7T7NS-Memphis
pcDNA3/Pol2/T7T7NS-Brevig Mission
pcDNA3/Pol2/T7T7NS(K227S)-Brevig Mission
pcDNA3/Pol2/T7T7NS-ZJU
pcDNA3/Pol2/T7T7NS-WF10

169

Formula for Reed-Muench Method

170

CURRICULUM VITA

Katherine Meraz was born on July 29, 1983 in El Paso, Texas. She graduated
from Parkland High School, El Paso, Texas, in the spring of 2001 and entered The
University of Texas at El Paso in the fall with the Lucille Stevens and Lawrence E. Baker
Scholarships. While pursuing a bachelor’s degree in microbiology, she was a member of
the Marching Miner Band and participated in Women in Science and Engineering
(WiSE). During the summer of 2001, she worked as an undergraduate researcher in the
laboratory of Dr. Robert Webb. After receiving her bachelor’s of science degree in the
fall of 2004, she worked as a technician in the laboratory of Dr. Kyle L. Johnson. In the
spring of 2006, Katherine accepted a position as a science teacher at Parkland High
School, where she taught for four years and served as department chair for two of those
years.
In the fall of 2010, she entered Graduate School at The University of Texas at El
Paso (UTEP), El Paso, Texas, to work in the laboratory of Dr. German Rosas-Acosta.
Her research has focused on the interaction between influenza A virus and the cellular
SUMOylation system. She has worked as a teaching assistant and research assistant in
the Department of Biological Sciences. From 2010 to 2011, she taught the General
Microbiology laboratories. In the fall of 2012, she was awarded a fellowship from the
National Science Foundation Graduate STEM Fellows in K-12 Education Program.
She has presented at the 2012 (poster) and 2013 (oral) American Society for
Virology conferences, where both years she was the recipient of graduate travel grants,
and at the First Annual Interdisciplinary Symposium: 21st Century Development in
171

Health Promoting Fields (2013). She has had her research presented at several other
conferences, including the Sixth International Conference on SUMO, Ubiquitin, and
UBL Proteins: Targets for Human Diseases (2012), Annual Biomedical Research
Conference for Minority Students (ABRCMS) (2013), and Campus Office for
Undergraduate Research Initiatives (COURI) Symposia (2014).
She has already published one peer-reviewed paper as a co-author and soon will
publish at least two articles as first author and two as co-author. After graduation, she
hopes to utilize her degree through the development of programs to enrich STEM
teaching and learning within the El Paso border region.

Permanent Address:

11037 Wedge Ln.
El Paso, Texas 79934
USA

This dissertation was typed by Katherine Anne Meraz.

172

